#  @Redeye_ Redeye Redeye posts on X about ceo, comments, $avt, strong the most. They currently have [------] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours. ### Engagements: [---] [#](/creator/twitter::153838561/interactions)  - [--] Week [------] +56% - [--] Month [------] +60% - [--] Months [-------] -23% - [--] Year [---------] -11% ### Mentions: [--] [#](/creator/twitter::153838561/posts_active)  - [--] Week [--] +85% - [--] Month [---] -1.70% - [--] Months [-----] -3.40% - [--] Year [-----] +55% ### Followers: [------] [#](/creator/twitter::153838561/followers)  - [--] Week [------] no change - [--] Month [------] -0.14% - [--] Months [------] -0.52% - [--] Year [------] -1.30% ### CreatorRank: [---------] [#](/creator/twitter::153838561/influencer_rank)  ### Social Influence **Social category influence** [cryptocurrencies](/list/cryptocurrencies) 23.28% [finance](/list/finance) 7.41% [stocks](/list/stocks) 6.35% [exchanges](/list/exchanges) 3.17% [countries](/list/countries) 2.65% [gaming](/list/gaming) 0.53% **Social topic influence** [ceo](/topic/ceo) 4.76%, [comments](/topic/comments) 4.23%, [$avt](/topic/$avt) #7, [strong](/topic/strong) 3.7%, [$ace](/topic/$ace) 3.17%, [ace](/topic/ace) 3.17%, [$fpip](/topic/$fpip) 3.17%, [$lagr](/topic/$lagr) 2.65%, [$htro](/topic/$htro) 2.65%, [growth](/topic/growth) 2.65% **Top accounts mentioned or mentioned by** [@formpipe](/creator/undefined) [@vidhance](/creator/undefined) [@heliospectra](/creator/undefined) [@qwertyrius](/creator/undefined) [@lindstroemk](/creator/undefined) [@mrchaarless](/creator/undefined) **Top assets mentioned** [Aventus (AVT)](/topic/$avt) [Fusionist (ACE)](/topic/$ace) [Raydium (RAY)](/topic/$ray) [Coldstack (CLS)](/topic/$cls) [Evotec SE (EVO)](/topic/$evo) [BioAge Labs, Inc. (BIOA)](/topic/$bioa) [Inspect (INSP)](/topic/$insp) [iMe Lab (LIME)](/topic/$lime) [Cemex S.A.B. de C.V. (CX)](/topic/$cx) [Bware (INFRA)](/topic/$infra) [Deere & Company (DE)](/topic/$de) [MobileCoin (MOB)](/topic/$mob) [Initia (INIT)](/topic/$init) [Annexon, Inc. (ANNX)](/topic/$annx) [Nitro League (NITRO)](/topic/$nitro) [Starbase (STAR)](/topic/$star) ### Top Social Posts Top posts by engagements in the last [--] hours "Redeye considers I-Tech's Q4 report to be soft although the company faced relatively high set expectations and tough comps. $ITECH https://www.redeye.se/research/1146854/i-tech-q4-initial-take-softer-than-expected-top-line https://www.redeye.se/research/1146854/i-tech-q4-initial-take-softer-than-expected-top-line" [X Link](https://x.com/Redeye_/status/2019336991561904558) 2026-02-05T09:07Z 14.4K followers, [---] engagements "Redeye har intervjuat I-Techs vd Markus Jnsson angende Q4 rapporten. $ITECH https://www.redeye.se/research/1147207/i-tech-q4-intervju-redeye-pratar-med-vd-markus-jonsson https://www.redeye.se/research/1147207/i-tech-q4-intervju-redeye-pratar-med-vd-markus-jonsson" [X Link](https://x.com/Redeye_/status/2019773125521531107) 2026-02-06T14:00Z 14.4K followers, [---] engagements "Redeye comments on Tradedoubler's Q4 report showcasing solid underlying execution in a cautious market environment. $TRAD https://www.redeye.se/research/1143262/tradedoubler-q4-review-double-digit-metapic-single-digit-multiple https://www.redeye.se/research/1143262/tradedoubler-q4-review-double-digit-metapic-single-digit-multiple" [X Link](https://x.com/Redeye_/status/2022234556745879863) 2026-02-13T09:01Z 14.4K followers, [---] engagements "Redeye notes that Devyser delivered sales relatively in line with expectations but the star of the show was the excellent EBIT margin of 25% thanks to continued impressive cost control and returning Thermo Fisher sales. $DVYSR https://www.redeye.se/research/1149851/devyser-diagnostics-q4-review-jaw-dropping-ebit-margin https://www.redeye.se/research/1149851/devyser-diagnostics-q4-review-jaw-dropping-ebit-margin" [X Link](https://x.com/Redeye_/status/2022235972994507059) 2026-02-13T09:06Z 14.4K followers, [---] engagements "Redeye comments on Annexins Q4 report and recent events and see good initial progress in the phase II study. $ANNX https://www.redeye.se/research/1147539/annexin-pharmaceuticals-q4-review-phase-ii-study-away-with-positive-initial-results https://www.redeye.se/research/1147539/annexin-pharmaceuticals-q4-review-phase-ii-study-away-with-positive-initial-results" [X Link](https://x.com/Redeye_/status/2019772449588387979) 2026-02-06T13:57Z 14.4K followers, [---] engagements "Redeye comments on Active Biotech's fourth quarter report. $ACTI https://www.redeye.se/research/1150157/active-biotech-q4-review-tasqinimod-recruiting-again https://www.redeye.se/research/1150157/active-biotech-q4-review-tasqinimod-recruiting-again" [X Link](https://x.com/Redeye_/status/2022267097510711664) 2026-02-13T11:10Z 14.4K followers, [---] engagements "Redeye's view of Genovis Q2 report is balanced sales were largely in line but profitability was softer than we had estimated. $GENO http://redeye.se/research/1121748/genovis-q2-2025-initial-comments http://redeye.se/research/1121748/genovis-q2-2025-initial-comments" [X Link](https://x.com/Redeye_/status/1955189857602469971) 2025-08-12T08:49Z 14.4K followers, [----] engagements "Redeye notes an interesting press release from Genovis confirming a SEK11m order from a global pharmaceutical company. $GENO https://www.redeye.se/research/1131032/genovis-eur1m-order-strengthening-the-outlook https://www.redeye.se/research/1131032/genovis-eur1m-order-strengthening-the-outlook" [X Link](https://x.com/Redeye_/status/1980136900909584869) 2025-10-20T05:00Z 14.4K followers, [----] engagements "Redeye provides an initial comment on the Q3 [----] report from Sdiptech where adjusted EBITA came in exactly in line with our forecasts although stronger than consensus. $SDIP https://www.redeye.se/research/1132080/sdiptech-q3-initial-take-adj-ebita-in-line-with-estimates https://www.redeye.se/research/1132080/sdiptech-q3-initial-take-adj-ebita-in-line-with-estimates" [X Link](https://x.com/Redeye_/status/1981616305393254759) 2025-10-24T06:58Z 14.4K followers, [---] engagements "Redeye has interviewed Lagercrantzs CEO Jrgen Wigh. $LAGR https://www.redeye.se/research/1132817/lagercrantz-q2-interview-redeye-speaks-with-ceo-jorgen-wigh https://www.redeye.se/research/1132817/lagercrantz-q2-interview-redeye-speaks-with-ceo-jorgen-wigh" [X Link](https://x.com/Redeye_/status/1981685121410580791) 2025-10-24T11:32Z 14.4K followers, [---] engagements "Redeye updates its estimates and valuation after Lagercrantzs Q2 2025/2026 report. $LAGR https://www.redeye.se/research/1133217/lagercrantz-q3-review-strong-ma-pipeline https://www.redeye.se/research/1133217/lagercrantz-q3-review-strong-ma-pipeline" [X Link](https://x.com/Redeye_/status/1982732115965034722) 2025-10-27T08:52Z 14.4K followers, [---] engagements "Redeye reviews SynAct Pharma's Q3 report. $SYNACT https://www.redeye.se/research/1133751/synact-q3-update-advance-approaching-full-recruitment https://www.redeye.se/research/1133751/synact-q3-update-advance-approaching-full-recruitment" [X Link](https://x.com/Redeye_/status/1984162179197943818) 2025-10-31T07:35Z 14.4K followers, [---] engagements "Hexatronic is trading below Redeyes Base Case. We spoke with our analyst about the stronger-than-expected momentum in the Data Center segment main sources of income and other key topics. This is a premium article included in our paid plans from SEK 99/month. $HTRO https://www.redeye.se/research/1138115/hexatronic https://www.redeye.se/research/1138115/hexatronic" [X Link](https://x.com/Redeye_/status/1988174022085931086) 2025-11-11T09:16Z 14.4K followers, [----] engagements "Redeye takes a positive stance towards Vertiseits acquisition of Muse expanding the offering into a new related area which is going through a major transformation. $VERT https://www.redeye.se/research/1140069/vertiseit-entering-audio-as-ai-transforms-the-market https://www.redeye.se/research/1140069/vertiseit-entering-audio-as-ai-transforms-the-market" [X Link](https://x.com/Redeye_/status/1991506920323076384) 2025-11-20T14:00Z 14.4K followers, [---] engagements "Vitrolife is trading below Redeyes Bear Case. We spoke with our analyst about what drives Vitrolife's competitive position in the global IVF market how sustainable gross margins above 60% are in core segments and other key topics. This is a premium article included in our paid plans from SEK 99/month. $VITR https://www.redeye.se/research/1146054/vitrolife https://www.redeye.se/research/1146054/vitrolife" [X Link](https://x.com/Redeye_/status/2016078157955162133) 2026-01-27T09:17Z 14.4K followers, [---] engagements "Redeye comments on Avtech releasing their preliminary figures for Q4 [----] which fell short of Redeye expectations on both sales and EBITDA. $AVT https://www.redeye.se/research/1146122/avtech-q4-preliminary-figures-sales-miss-due-to-postponed-sales https://www.redeye.se/research/1146122/avtech-q4-preliminary-figures-sales-miss-due-to-postponed-sales" [X Link](https://x.com/Redeye_/status/2016146732346658999) 2026-01-27T13:50Z 14.4K followers, [----] engagements "Redeye provides its initial take on Indutrades Q4 [----] report which missed on earnings mainly due to two relatively large project write-downs in the UK. $INDT https://www.redeye.se/research/1146294/indutrade-q4-initial-take-project-write-downs-hurt-ebita https://www.redeye.se/research/1146294/indutrade-q4-initial-take-project-write-downs-hurt-ebita" [X Link](https://x.com/Redeye_/status/2016928867076718844) 2026-01-29T17:38Z 14.4K followers, [---] engagements "Redeye provides its initial take on Lifcos Q4 [----] report which missed our projections by 3% on sales and 5% on EBITA. $LIFCO https://www.redeye.se/research/1146457/lifco-q4-initial-take-slight-miss-driven-by-dental-and-demolition-tools https://www.redeye.se/research/1146457/lifco-q4-initial-take-slight-miss-driven-by-dental-and-demolition-tools" [X Link](https://x.com/Redeye_/status/2018202726400970779) 2026-02-02T06:00Z 14.4K followers, [---] engagements "Redeye comments on Vitrolifes Q4 report coming in very close to our projections reflecting modest underlying growth and a significant reported EBIT loss driven by the goodwill impairment announced in December. $VITR https://www.redeye.se/research/1145964/vitrolife-q4-initial-take-aligned-nicely-with-estimates https://www.redeye.se/research/1145964/vitrolife-q4-initial-take-aligned-nicely-with-estimates" [X Link](https://x.com/Redeye_/status/2018607395811864881) 2026-02-03T08:48Z 14.4K followers, [---] engagements "Redeye has interviewed SynAct Pharma's CSO Thomas Jonassen about a new investigator-sponsored phase II study of resomelagon in viral infections. $SYNACT https://www.redeye.se/research/1146848/synact-pharma-interview-redeye-speaks-with-cso-thomas-jonassen https://www.redeye.se/research/1146848/synact-pharma-interview-redeye-speaks-with-cso-thomas-jonassen" [X Link](https://x.com/Redeye_/status/2018675128075268473) 2026-02-03T13:17Z 14.4K followers, [---] engagements "Redeye updates its estimates and valuation after Lifcos Q4 [----] report. $LIFCO https://www.redeye.se/research/1146626/lifco-q4-review-steady-as-she-goes https://www.redeye.se/research/1146626/lifco-q4-review-steady-as-she-goes" [X Link](https://x.com/Redeye_/status/2018957967325077582) 2026-02-04T08:01Z 14.4K followers, [---] engagements "Redeye comments on the current valuation profile of Vitrolife requiring more than the current stagnant growth profile yesterdays 20% sell-off (despite a report largely in line with Redeyes estimates) appears excessive. $VITR https://www.redeye.se/research/1140910/vitrolife-q4-review-excessive-selloff-improves-risk-reward-in-the-stock https://www.redeye.se/research/1140910/vitrolife-q4-review-excessive-selloff-improves-risk-reward-in-the-stock" [X Link](https://x.com/Redeye_/status/2018958304203157993) 2026-02-04T08:02Z 14.4K followers, [---] engagements "Redeye comments on Smart Eyes acquisition of Sightic which removes the most meaningful competitive threat in camera-based alcohol impairment detection and positions the company to dominate what we believe will become a standard safety feature layered on top of DMS. $SEYE https://www.redeye.se/research/1147199/smart-eye-checkmate-on-drunk-driving https://www.redeye.se/research/1147199/smart-eye-checkmate-on-drunk-driving" [X Link](https://x.com/Redeye_/status/2019322800297648143) 2026-02-05T08:10Z 14.4K followers, [---] engagements "Redeye comments on Hexatronics Q4 report showing solid overall numbers driven by a further acceleration in Data Center. $HTRO https://www.redeye.se/research/1146077/hexatronic-q4-initial-take-strong-adjusted-numbers-accelerating-growth-in-data-center https://www.redeye.se/research/1146077/hexatronic-q4-initial-take-strong-adjusted-numbers-accelerating-growth-in-data-center" [X Link](https://x.com/Redeye_/status/2019323169841246698) 2026-02-05T08:12Z 14.4K followers, [---] engagements "Redeye comments on Evolutions Q4-results which were close to our forecasts albeit with soft revenue in Europe while LatAm and Asia were slightly stronger than expected. $EVO https://www.redeye.se/research/1147410/evolution-q4-initial-take-close-to-our-expectations https://www.redeye.se/research/1147410/evolution-q4-initial-take-close-to-our-expectations" [X Link](https://x.com/Redeye_/status/2019323641348124876) 2026-02-05T08:14Z 14.4K followers, [----] engagements "Redeye comments on Fractal Gaming Groups Q4 [----] report which came in below our expectations. $FRACTL https://www.redeye.se/research/1145586/fractal-q4-initial-take-tough-macro-weighs-on-profitability https://www.redeye.se/research/1145586/fractal-q4-initial-take-tough-macro-weighs-on-profitability" [X Link](https://x.com/Redeye_/status/2019323790942216562) 2026-02-05T08:14Z 14.4K followers, [---] engagements "Redeye has interviewed Hexatronic's CEO Rikard Frberg about the fourth quarter and how the company manages to growth fast within Data Center. $HTRO https://www.redeye.se/research/1147202/hexatronic-q4-interview-redeye-speaks-with-ceo-rikard-froberg https://www.redeye.se/research/1147202/hexatronic-q4-interview-redeye-speaks-with-ceo-rikard-froberg" [X Link](https://x.com/Redeye_/status/2019337288304730544) 2026-02-05T09:08Z 14.4K followers, [---] engagements "Redeye presents its preview of RaySearchs Q4 [----] results due on February [--]. $RAY https://www.redeye.se/research/1147593/raysearch-q4-preview-possibilities-for-a-beaming-end-to-2025 https://www.redeye.se/research/1147593/raysearch-q4-preview-possibilities-for-a-beaming-end-to-2025" [X Link](https://x.com/Redeye_/status/2019394833509646347) 2026-02-05T12:57Z 14.4K followers, [---] engagements "Redeye updates on Evolution post Q4-results which were close to our forecasts while the companys margin guidance for [----] was also in line with expectations. $EVO https://www.redeye.se/research/1147724/evolution-q4-review-asia-and-europe-continue-to-hold-back-growth https://www.redeye.se/research/1147724/evolution-q4-review-asia-and-europe-continue-to-hold-back-growth" [X Link](https://x.com/Redeye_/status/2019689175575077375) 2026-02-06T08:26Z 14.4K followers, [----] engagements "Redeye comments on Vitecs Q4 report. $VIT https://www.redeye.se/research/1146086/vitec-q4-initial-take-clearly-beating-modest-expectations https://www.redeye.se/research/1146086/vitec-q4-initial-take-clearly-beating-modest-expectations" [X Link](https://x.com/Redeye_/status/2019689513006899228) 2026-02-06T08:27Z 14.4K followers, [---] engagements "Redeye provides its initial take on CTEKs Q4 numbers where sales were slightly lower than expected but profitability greatly exceeded our expectations. $CTEK https://www.redeye.se/research/1147826/ctek-q4-initial-take-higher-profit-levels-than-expected https://www.redeye.se/research/1147826/ctek-q4-initial-take-higher-profit-levels-than-expected" [X Link](https://x.com/Redeye_/status/2019689646217904413) 2026-02-06T08:28Z 14.4K followers, [---] engagements "Redeye provides its initial take on Lagercrantzs Q3 2025/2026 report which showed strong EBITA growth of 20% y/y beating our forecast by 5%. $LAGR https://www.redeye.se/research/1147841/lagercrantz-q3-initial-take-strong-numbers-raised-ambition https://www.redeye.se/research/1147841/lagercrantz-q3-initial-take-strong-numbers-raised-ambition" [X Link](https://x.com/Redeye_/status/2019690054353084650) 2026-02-06T08:30Z 14.4K followers, [---] engagements "Redeye takes a slightly more positive view following Hexatronic's Q4 report showing even stronger momentum in Data Center. $HTRO https://www.redeye.se/research/1146071/hexatronic-q4-review-in-good-shape-for-2026 https://www.redeye.se/research/1146071/hexatronic-q4-review-in-good-shape-for-2026" [X Link](https://x.com/Redeye_/status/2019773387912937890) 2026-02-06T14:01Z 14.4K followers, [---] engagements "Redeye comments on Fractals share price falling sharply as the market prices in prolonged weakness in PC demand and elevated uncertainty around profitability in [----]. $FRACTL https://www.redeye.se/research/1145688/fractal-gaming-group-q4-review-patience-will-be-rewarded https://www.redeye.se/research/1145688/fractal-gaming-group-q4-review-patience-will-be-rewarded" [X Link](https://x.com/Redeye_/status/2019773995160056187) 2026-02-06T14:03Z 14.4K followers, [---] engagements "Redeye strengthens its positive view of Vitec following the Q4 report. $VIT https://www.redeye.se/research/1146081/vitec-q4-review-solid-operations-and-acquisitions-as-usual-in-ai-driven-market-volatility https://www.redeye.se/research/1146081/vitec-q4-review-solid-operations-and-acquisitions-as-usual-in-ai-driven-market-volatility" [X Link](https://x.com/Redeye_/status/2020784039557263660) 2026-02-09T08:57Z 14.4K followers, [---] engagements "Redeye har intervjuat CTEKs vd Henrik Fagrenius efter fredagens Q4-rapport som visade lgre omsttning jmfrt med fregende r men en kraftigt frbttrad lnsamhet och ett starkt kassaflde. $CTEK https://www.redeye.se/research/1147995/ctek-q4-intervju-redeye-pratar-med-vd-henrik-fagrenius https://www.redeye.se/research/1147995/ctek-q4-intervju-redeye-pratar-med-vd-henrik-fagrenius" [X Link](https://x.com/Redeye_/status/2020785111843623366) 2026-02-09T09:01Z 14.4K followers, [---] engagements "Redeye updates its estimates and valuation after Lagercrantzs Q3 2025/2026 report. $LAGR https://www.redeye.se/research/1148071/lagercrantz-q3-review-demand-is-picking-up https://www.redeye.se/research/1148071/lagercrantz-q3-review-demand-is-picking-up" [X Link](https://x.com/Redeye_/status/2020785564962763071) 2026-02-09T09:03Z 14.4K followers, [---] engagements "Redeye briefly comments on BioArctic's Q4 royalties for Leqembi which came in roughly as expected. $BIOA https://www.redeye.se/research/1147992/bioarctic-q4-royalties-roughly-in-line https://www.redeye.se/research/1147992/bioarctic-q4-royalties-roughly-in-line" [X Link](https://x.com/Redeye_/status/2020786156795785268) 2026-02-09T09:05Z 14.4K followers, [---] engagements "Redeye has interviewed Fractal Gaming Groups CEO Jonas Holst who shares key insights from the Q4 report the current market environment and how the category expansion is unfolding. $FRACTL https://www.redeye.se/research/1147991/fractal-gaming-group-q4-interview-redeye-speaks-with-ceo-jonas-holst https://www.redeye.se/research/1147991/fractal-gaming-group-q4-interview-redeye-speaks-with-ceo-jonas-holst" [X Link](https://x.com/Redeye_/status/2020786448228597883) 2026-02-09T09:06Z 14.4K followers, [---] engagements "Redeye has interviewed Lagercrantzs CEO Jrgen Wigh. $LAGR https://www.redeye.se/research/1148227/lagercrantz-q3-interview-redeye-speaks-with-ceo-jorgen-wigh https://www.redeye.se/research/1148227/lagercrantz-q3-interview-redeye-speaks-with-ceo-jorgen-wigh" [X Link](https://x.com/Redeye_/status/2020881653577445481) 2026-02-09T15:25Z 14.4K followers, [---] engagements "Redeye returns with an update following Ascelia Pharma's Q4 update which contained no material surprises. $ACE https://www.redeye.se/research/1148258/ascelia-pharma-q4-review-on-the-path-to-approval https://www.redeye.se/research/1148258/ascelia-pharma-q4-review-on-the-path-to-approval" [X Link](https://x.com/Redeye_/status/2021143157799260322) 2026-02-10T08:44Z 14.4K followers, [---] engagements "Redeye provides an initial comment on the Q4 [----] report from Sdiptech where adjusted EBITA in core operations came in exactly in line with our forecasts and consensus. $SDIP https://www.redeye.se/research/1148192/sdiptech-q4-initial-take-divestments-are-progressing-adj-ebita-in-line https://www.redeye.se/research/1148192/sdiptech-q4-initial-take-divestments-are-progressing-adj-ebita-in-line" [X Link](https://x.com/Redeye_/status/2021143414188695729) 2026-02-10T08:45Z 14.4K followers, [---] engagements "Redeye updates its view following CTEKs Q4 report. $CTEK https://www.redeye.se/research/1148634/ctek-q4-review-2026-a-harvesting-year-for-product-investments https://www.redeye.se/research/1148634/ctek-q4-review-2026-a-harvesting-year-for-product-investments" [X Link](https://x.com/Redeye_/status/2021508597088182279) 2026-02-11T08:56Z 14.4K followers, [---] engagements "Redeye provides a research update after Optomeds Q4 [----] report. $OPTOMED https://www.redeye.se/research/1148555/optomed-q4-review-devices-segment-growth-supports-outlook-despite-cautious-guidance https://www.redeye.se/research/1148555/optomed-q4-review-devices-segment-growth-supports-outlook-despite-cautious-guidance" [X Link](https://x.com/Redeye_/status/2021508718123209140) 2026-02-11T08:56Z 14.4K followers, [---] engagements "Redeye updates its estimates and valuation following MedCaps Q4 [----] report. $MCAP https://www.redeye.se/research/1148546/medcap-q4-review-beat-on-solid-organic-growth https://www.redeye.se/research/1148546/medcap-q4-review-beat-on-solid-organic-growth" [X Link](https://x.com/Redeye_/status/2021508948235301312) 2026-02-11T08:57Z 14.4K followers, [---] engagements "Redeye has interviewed Gapwaves' CEO Jonas Ehinger to unpack a strong Q4 rapidly increasing volumes and what the transition to manufacturing partner Frencken means for margins and the path to profitability. $GAPW https://www.redeye.se/research/1148262/gapwaves-q4-interview-redeye-speaks-with-ceo-jonas-ehinger https://www.redeye.se/research/1148262/gapwaves-q4-interview-redeye-speaks-with-ceo-jonas-ehinger" [X Link](https://x.com/Redeye_/status/2021509167111102641) 2026-02-11T08:58Z 14.4K followers, [---] engagements "Redeye updates on EG7 ahead of Q4-results (due [--] February) where we expect the results to remain largely stable compared to Q3 as currency headwind counteracts positive seasonality. $EG7 https://www.redeye.se/research/1148675/eg7-q4-preview-continued-fx-headwind https://www.redeye.se/research/1148675/eg7-q4-preview-continued-fx-headwind" [X Link](https://x.com/Redeye_/status/2021509314658357424) 2026-02-11T08:59Z 14.4K followers, [---] engagements "Redeye comments on Hansa Biopharma's Q4 report. $HNSA https://www.redeye.se/research/1148656/hansa-biopharma-q4-initial-take-strong-european-sales-beats-forecast https://www.redeye.se/research/1148656/hansa-biopharma-q4-initial-take-strong-european-sales-beats-forecast" [X Link](https://x.com/Redeye_/status/2021520744065441819) 2026-02-11T09:44Z 14.4K followers, [---] engagements "Redeye comments briefly on Insplorions announcement following the Boards strategic review. $INSP https://www.redeye.se/research/1148847/insplorion-divesting-its-core-business https://www.redeye.se/research/1148847/insplorion-divesting-its-core-business" [X Link](https://x.com/Redeye_/status/2021598710312939866) 2026-02-11T14:54Z 14.4K followers, [---] engagements "Redeye comments on Devyser reaching a 25% EBIT margin and record sales with strong operating cash flow. We expect the share to trade upwards 15% today. $DVYSR https://www.redeye.se/research/1149167/devyser-q4-initial-take-a-strong-end-to-2025 https://www.redeye.se/research/1149167/devyser-q4-initial-take-a-strong-end-to-2025" [X Link](https://x.com/Redeye_/status/2021875204121583725) 2026-02-12T09:13Z 14.4K followers, [---] engagements "Redeye provides its first take on Camurus Q4 report [----] published this morning. $CAMX https://www.redeye.se/research/1149158/camurus-q4-initial-take-europe-continued-decline-us-growth https://www.redeye.se/research/1149158/camurus-q4-initial-take-europe-continued-decline-us-growth" [X Link](https://x.com/Redeye_/status/2021883544004706324) 2026-02-12T09:46Z 14.4K followers, [---] engagements "Redeye comments on Tradedoubler's Q4 report being impacted by a significant revaluation of the KaHa earnout liability which masked a relatively stable underlying performance. $TRAD https://www.redeye.se/research/1143265/tradedoubler-q4-initial-take-underlying-performance-largely-in-line https://www.redeye.se/research/1143265/tradedoubler-q4-initial-take-underlying-performance-largely-in-line" [X Link](https://x.com/Redeye_/status/2021883828457923061) 2026-02-12T09:47Z 14.4K followers, [---] engagements "Redeye provides its initial take on Ferroamps Q4 numbers which presented strong sales growth and significantly improved profitability y-o-y. $FERRO https://www.redeye.se/research/1149240/ferroamp-q4-initial-take-very-strong-sales-development https://www.redeye.se/research/1149240/ferroamp-q4-initial-take-very-strong-sales-development" [X Link](https://x.com/Redeye_/status/2021883994212548824) 2026-02-12T09:48Z 14.4K followers, [---] engagements "Redeye provides its initial take on Acarixs Q4 report which beat our topline estimates while costs were somewhat higher than we had anticipated. $ACARIX https://www.redeye.se/research/1149270/acarix-q4-inital-take-beat-on-topline https://www.redeye.se/research/1149270/acarix-q4-inital-take-beat-on-topline" [X Link](https://x.com/Redeye_/status/2021884394399506653) 2026-02-12T09:49Z 14.4K followers, [---] engagements "Redeye comments on Litiums Q4 which showed solid momentum with 18% ARR growth and net sales above our expectations. $LITI https://www.redeye.se/research/1148277/litium-q4-initial-take-record-order-intake https://www.redeye.se/research/1148277/litium-q4-initial-take-record-order-intake" [X Link](https://x.com/Redeye_/status/2021884516567339498) 2026-02-12T09:50Z 14.4K followers, [---] engagements "Redeye's immediate impression of Stille's year-end report [----] is positive. $STIL https://www.redeye.se/research/1146011/stille-q4-initial-take-beat-across-the-board-despite-fx-headwinds https://www.redeye.se/research/1146011/stille-q4-initial-take-beat-across-the-board-despite-fx-headwinds" [X Link](https://x.com/Redeye_/status/2021884891521053026) 2026-02-12T09:51Z 14.4K followers, [---] engagements "Redeye notes that as anticipated Genovis year-end report showcased robust top-line momentum with sharp sales growth following the SEK 11m ADC-order announced in Q4. $GENO https://www.redeye.se/research/1146004/genovis-q4-initial-take-in-line-with-our-estimates https://www.redeye.se/research/1146004/genovis-q4-initial-take-in-line-with-our-estimates" [X Link](https://x.com/Redeye_/status/2021886218984993230) 2026-02-12T09:56Z 14.4K followers, [---] engagements "Redeye considers Polygienes Q4'25 figures to be soft missing our expectations by 18% on top-line primarily driven by lower Polygiene sales. $POLYG https://www.redeye.se/research/1148755/polygiene-group-q4-initial-take-softer-than-expected https://www.redeye.se/research/1148755/polygiene-group-q4-initial-take-softer-than-expected" [X Link](https://x.com/Redeye_/status/2021886458705874972) 2026-02-12T09:57Z 14.4K followers, [---] engagements "Redeye comments on Hansa Biopharma's Q4 report. $HNSA https://www.redeye.se/research/1148786/hansa-biopharma-q4-update-strong-quarter-in-europe https://www.redeye.se/research/1148786/hansa-biopharma-q4-update-strong-quarter-in-europe" [X Link](https://x.com/Redeye_/status/2021898459910222200) 2026-02-12T10:45Z 14.4K followers, [---] engagements "Redeye notes that AVTECH's Q4 [----] results aligned with preliminary figures whilst falling short of the firm's estimates by 11% on sales and 10% on adjusted EBITDA. $AVT https://www.redeye.se/research/1147769/avtech-q4-initial-take-pre-announced-results-set-stage-for-modest-base-case-recalibration https://www.redeye.se/research/1147769/avtech-q4-initial-take-pre-announced-results-set-stage-for-modest-base-case-recalibration" [X Link](https://x.com/Redeye_/status/2019689881518395650) 2026-02-06T08:29Z 14.4K followers, [---] engagements "Redeye revises its base case to SEK10(SEK12) following AVTECH's Q4 [----] results which fell 11% short on net sales owing to anticipated contracts failing to materialise. $AVT https://www.redeye.se/research/1148102/avtech-q4-review-40-de-rating-leads-to-increasingly-compelling-setup https://www.redeye.se/research/1148102/avtech-q4-review-40-de-rating-leads-to-increasingly-compelling-setup" [X Link](https://x.com/Redeye_/status/2020784363210740141) 2026-02-09T08:58Z 14.4K followers, [---] engagements "Redeye has interviewed AVTECHs CEO David Rytter to discuss the past year future development and the current sales pipeline. $AVT https://www.redeye.se/research/1147928/avtech-q4-interview-redeye-speaks-with-ceo-david-ritter https://www.redeye.se/research/1147928/avtech-q4-interview-redeye-speaks-with-ceo-david-ritter" [X Link](https://x.com/Redeye_/status/2020785418094948724) 2026-02-09T09:02Z 14.4K followers, [---] engagements "Redeye comments on SynAct Pharma's full recruitment of the phase IIb ADVANCE study in RA with [---] patients. $SYNACT https://www.redeye.se/research/1148168/synact-pharma-last-patient-included https://www.redeye.se/research/1148168/synact-pharma-last-patient-included" [X Link](https://x.com/Redeye_/status/2020785744059470244) 2026-02-09T09:04Z 14.4K followers, [---] engagements "Redeye retains its positive view of CombinedX following the Q4 report. $CX https://www.redeye.se/research/1148430/combinedx-q4-initial-take-solid-underlying-profitability-slightly-revised-strategy https://www.redeye.se/research/1148430/combinedx-q4-initial-take-solid-underlying-profitability-slightly-revised-strategy" [X Link](https://x.com/Redeye_/status/2021520845294993763) 2026-02-11T09:45Z 14.4K followers, [---] engagements "Redeye comments on todays press release from Waystream announcing that Telia Estonia has placed a SEK9m follow-up order for access switches. $WAYS https://www.redeye.se/research/1149044/waystream-telia-estonia-scales-up-with-sek9m-order https://www.redeye.se/research/1149044/waystream-telia-estonia-scales-up-with-sek9m-order" [X Link](https://x.com/Redeye_/status/2021605527919198281) 2026-02-11T15:21Z 14.4K followers, [---] engagements "Redeye comments on Vertiseits Q4 report showing somewhat lower organic ARR growth and higher OPEX than expected. $VERT https://www.redeye.se/research/1148503/vertiseit-q4-initial-take-somewhat-soft-q4-positive-outlook https://www.redeye.se/research/1148503/vertiseit-q4-initial-take-somewhat-soft-q4-positive-outlook" [X Link](https://x.com/Redeye_/status/2021874456054944103) 2026-02-12T09:10Z 14.4K followers, [---] engagements "Redeye comments on Carasents Q4 report showing slightly lower organic ARR growth yet solid scalability. $CARA https://www.redeye.se/research/1148492/carasent-q4-initial-take-reaching-2025-targets https://www.redeye.se/research/1148492/carasent-q4-initial-take-reaching-2025-targets" [X Link](https://x.com/Redeye_/status/2021874737782063537) 2026-02-12T09:11Z 14.4K followers, [---] engagements "Redeye comments on RaySearch delivering a strong Q4 with record sales above consensus estimates and record EBIT also above consensus estimates. $RAY https://www.redeye.se/research/1149210/raysearch-laboratories-q4-initial-take-another-record-quarter https://www.redeye.se/research/1149210/raysearch-laboratories-q4-initial-take-another-record-quarter" [X Link](https://x.com/Redeye_/status/2021883065996394694) 2026-02-12T09:44Z 14.4K followers, [---] engagements "Redeye is encouraged by Nekkars financial recovery during the fourth quarter which posted a 30% beat on top-line and a [--] p.p stronger EBITDA margin compared to our relatively low set expectations. $NKR https://www.redeye.se/research/1148908/nekkar-q4-initial-take-better-than-expected https://www.redeye.se/research/1148908/nekkar-q4-initial-take-better-than-expected" [X Link](https://x.com/Redeye_/status/2021884189235118191) 2026-02-12T09:48Z 14.4K followers, [---] engagements "Redeye comments on Limes Q4 report showing 10% organic ARR growth slightly below our expectations. $LIME https://www.redeye.se/research/1148514/lime-q4-initial-take-slightly-below-expectations https://www.redeye.se/research/1148514/lime-q4-initial-take-slightly-below-expectations" [X Link](https://x.com/Redeye_/status/2021884805395189926) 2026-02-12T09:51Z 14.4K followers, [---] engagements "Redeye har intervjuat Active Biotechs vd Heln Tuvesson om Q4 rapporten med ett fokus p nyemissionen tasquinimod och laquinimod. $ACTI https://www.redeye.se/research/1149396/active-biotech-q4-intervju-redeye-pratar-med-vd-helen-tuvesson https://www.redeye.se/research/1149396/active-biotech-q4-intervju-redeye-pratar-med-vd-helen-tuvesson" [X Link](https://x.com/Redeye_/status/2021944327761703353) 2026-02-12T13:47Z 14.4K followers, [---] engagements "Redeye retains its positive view of CombinedX following a solid Q4 with strong underlying margins. $CX https://www.redeye.se/research/1148424/combinedx-q4-review-entering-2026-with-renewed-vision https://www.redeye.se/research/1148424/combinedx-q4-review-entering-2026-with-renewed-vision" [X Link](https://x.com/Redeye_/status/2022234069560689006) 2026-02-13T08:59Z 14.4K followers, [---] engagements "Redeye retains its positive view of Lime following the Q4 report. $LIME https://www.redeye.se/research/1148509/lime-q4-review-solid-fundamentals-despite-ai-squeeze https://www.redeye.se/research/1148509/lime-q4-review-solid-fundamentals-despite-ai-squeeze" [X Link](https://x.com/Redeye_/status/2022234377393148205) 2026-02-13T09:00Z 14.4K followers, [---] engagements "Redeye provides an update following Neola Medicals Q4 [----] report. $NEOLA https://www.redeye.se/research/1149522/neola-medical-q4-review-eyes-on-upcoming-clinical-data https://www.redeye.se/research/1149522/neola-medical-q4-review-eyes-on-upcoming-clinical-data" [X Link](https://x.com/Redeye_/status/2022234717458948214) 2026-02-13T09:01Z 14.4K followers, [---] engagements "Redeye updates on W5 Solutions following Q4 results that exceeded expectations. $W5 https://www.redeye.se/research/1149923/w5-solutions-q4-review-strong-year-end-and-positive-outlook https://www.redeye.se/research/1149923/w5-solutions-q4-review-strong-year-end-and-positive-outlook" [X Link](https://x.com/Redeye_/status/2022234836883370173) 2026-02-13T09:02Z 14.4K followers, [---] engagements "Redeye comments on Lytix' third quarter report [----]. $LYTIX https://www.redeye.se/research/1149495/lytix-biopharma-q4-review-well-funded-to-deliver-in-26 https://www.redeye.se/research/1149495/lytix-biopharma-q4-review-well-funded-to-deliver-in-26" [X Link](https://x.com/Redeye_/status/2022235004118733300) 2026-02-13T09:02Z 14.4K followers, [---] engagements "Redeye has interviewed Litium's CEO Martin Billenius who shares insights on the Q4 report the plans for [----] and the partnership with Monitor ERP. $LITI https://www.redeye.se/research/1149616/litium-q4-interview-redeye-speaks-with-ceo-martin-billenius https://www.redeye.se/research/1149616/litium-q4-interview-redeye-speaks-with-ceo-martin-billenius" [X Link](https://x.com/Redeye_/status/2022235299523543430) 2026-02-13T09:04Z 14.4K followers, [---] engagements "Redeye comments on Stilles soft share price developing over the past months to us appears more sentiment-driven than fundamental following the Q4 report. $STIL https://www.redeye.se/research/1148540/__trashed-2 https://www.redeye.se/research/1148540/__trashed-2" [X Link](https://x.com/Redeye_/status/2022236328029835503) 2026-02-13T09:08Z 14.4K followers, [---] engagements "Redeye views BeammWave's Q4 [----] report as a positive read with the share price likely to respond favourably to management's visible confidence better-than-expected cost discipline and continued momentum across all three customer verticals. $BEAMMW https://www.redeye.se/research/1149960/beammwave-q4-initial-take-execution-now-the-only-variable https://www.redeye.se/research/1149960/beammwave-q4-initial-take-execution-now-the-only-variable" [X Link](https://x.com/Redeye_/status/2022236482329833803) 2026-02-13T09:08Z 14.4K followers, [---] engagements "Redeye provides an update following Acarixs Q4 [----] report. $ACARIX https://www.redeye.se/research/1150002/acarix-q4-review-a-solid-end-to-2025 https://www.redeye.se/research/1150002/acarix-q4-review-a-solid-end-to-2025" [X Link](https://x.com/Redeye_/status/2022236742028566638) 2026-02-13T09:09Z 14.4K followers, [---] engagements "Redeye provides its initial take on Relais Q4 [----] report which featured an adjusted EBITA that aligned with our projection but a slightly soft organic growth amid a challenging market situation. $RELAIS https://www.redeye.se/research/1150093/relais-q4-initial-take-solid-profitability-softer-organic-growth https://www.redeye.se/research/1150093/relais-q4-initial-take-solid-profitability-softer-organic-growth" [X Link](https://x.com/Redeye_/status/2022236850438778883) 2026-02-13T09:10Z 14.4K followers, [---] engagements "Redeye sees Safetures Q4 [----] report to be another step in the right direction with positive ARR growth improving gross margin and solid cost control resulting in a positive EBIT. $SFTR https://www.redeye.se/research/1148745/safeture-q4-initial-take-sequential-improvements https://www.redeye.se/research/1148745/safeture-q4-initial-take-sequential-improvements" [X Link](https://x.com/Redeye_/status/2022237067267408205) 2026-02-13T09:11Z 14.4K followers, [---] engagements "Redeye has interviewed Invisios CEO Lars Hjgrd Hansen in connection with the company's Q4-results. $IVSO https://www.redeye.se/research/1150121/invisio-q4-interview-redeye-speaks-with-ceo-lars-hojgard-hansen https://www.redeye.se/research/1150121/invisio-q4-interview-redeye-speaks-with-ceo-lars-hojgard-hansen" [X Link](https://x.com/Redeye_/status/2022244125521948886) 2026-02-13T09:39Z 14.4K followers, [---] engagements "NanoEcho utvecklar framtidens rektalcancerdiagnostik. Idag startar teckningsperioden i bolagets fretrdesemission p upp till [----] MSEK fr att ta nsta steg med sin PoC-studie. Ls mer om transaktionen: Se VD Linda Perssons hisspitch: https://www.redeye.se/video/transaction/1149074/nanoecho-hisspitchutm_source=twitter&utm_medium=social&utm_campaign=nefeq126&utm_content=image https://www.redeye.se/transaction/nanoecho-ab-(publ)-utm_source=twitter&utm_medium=social&utm_campaign=nefeq126&utm_content=image" [X Link](https://x.com/Redeye_/status/2022249878651281584) 2026-02-13T10:01Z 14.4K followers, [---] engagements "Redeye updates on Better Collective ahead of Q4-results (due [--] February after market close) where we expect a solid year-end performance supported by positive seasonality. $BETCO https://www.redeye.se/research/1149964/better-collective-q4-preview-solid-year-end-expected https://www.redeye.se/research/1149964/better-collective-q4-preview-solid-year-end-expected" [X Link](https://x.com/Redeye_/status/2022235524157866374) 2026-02-13T09:04Z 14.4K followers, [---] engagements "Redeye has interviewed Acarix's CEO Aamir Mahmood following the release of the companys Q4 [----] report. $ACARIX https://www.redeye.se/research/1149628/acarix-q4-interview-redeye-speaks-with-ceo-aamir-mahmood https://www.redeye.se/research/1149628/acarix-q4-interview-redeye-speaks-with-ceo-aamir-mahmood" [X Link](https://x.com/Redeye_/status/2022264852983546011) 2026-02-13T11:01Z 14.4K followers, [---] engagements "Redeye keeps its positive view of Vertiseit following a decent Q4 report. $VERT https://www.redeye.se/research/1148498/vertiseit-q4-review-long-term-story-intact-ai-resilience-from-the-back-end https://www.redeye.se/research/1148498/vertiseit-q4-review-long-term-story-intact-ai-resilience-from-the-back-end" [X Link](https://x.com/Redeye_/status/2022233927654814174) 2026-02-13T08:58Z 14.4K followers, [---] engagements "Redeye returns with an update on Sprint Bioscience following recent events and the Q4 report. $SPRINT https://www.redeye.se/research/1148578/sprint-bioscience-q4-review-promising-development https://www.redeye.se/research/1148578/sprint-bioscience-q4-review-promising-development" [X Link](https://x.com/Redeye_/status/2022248906458062884) 2026-02-13T09:58Z 14.4K followers, [---] engagements "Redeye concludes that Litium delivered a strong Q4 with ARR growth of 18% including Geins and organic growth of 9%. $LITI https://www.redeye.se/research/1148574/litium-q4-review-adding-growth-to-the-basket-in-h2 https://www.redeye.se/research/1148574/litium-q4-review-adding-growth-to-the-basket-in-h2" [X Link](https://x.com/Redeye_/status/2022321815838720375) 2026-02-13T14:47Z 14.4K followers, [---] engagements "Redeye publishes a preview of Transtemas Q2 report. $TRANS https://www.redeye.se/research/1117172/transtema-q2-preview-breakthrough-deal-in-power-and-lowered-short-term-margin-assumptions https://www.redeye.se/research/1117172/transtema-q2-preview-breakthrough-deal-in-power-and-lowered-short-term-margin-assumptions" [X Link](https://x.com/Redeye_/status/1943203249156428260) 2025-07-10T06:58Z 14.5K followers, [---] engagements "Redeye is growing more optimistic about the investment case in Oncopeptides after two news items this week: the inclusion of Pepaxti in the EHA-EMN guidelines and strong sales growth in Q2. $ONCO https://www.redeye.se/research/1117317/oncopeptides-positive-momentum https://www.redeye.se/research/1117317/oncopeptides-positive-momentum" [X Link](https://x.com/Redeye_/status/1943234084295090322) 2025-07-10T09:01Z 14.5K followers, [----] engagements "Redeye har intervjuat Nanologicas vd Andreas Bhagwani. Vi diskuterar bland annat Q2-rapporten framsteg i produktionen nya kunder i USA&Kina och kassapositionen. $NICA https://www.redeye.se/research/1117374/nanologica-q225-intervju-med-vd-andreas-bhagwani https://www.redeye.se/research/1117374/nanologica-q225-intervju-med-vd-andreas-bhagwani" [X Link](https://x.com/Redeye_/status/1943336899118018725) 2025-07-10T15:49Z 14.5K followers, [---] engagements "Redeye updates its production estimates ahead of Arise's Q2 report on Friday next week (18 July). $ARISE https://www.redeye.se/research/1117621/arise-updated-estimates-ahead-of-the-q2-report https://www.redeye.se/research/1117621/arise-updated-estimates-ahead-of-the-q2-report" [X Link](https://x.com/Redeye_/status/1943554447763739048) 2025-07-11T06:14Z 14.5K followers, [---] engagements "Redeye updates its view on Nanologica following the Q2 report. $NICA https://www.redeye.se/research/1116790/nanologica-q2-2025-low-near-term-visibility-but-encouraging-long-term-case https://www.redeye.se/research/1116790/nanologica-q2-2025-low-near-term-visibility-but-encouraging-long-term-case" [X Link](https://x.com/Redeye_/status/1943554594568569172) 2025-07-11T06:14Z 14.5K followers, [----] engagements "Redeye comments on Limes Q2 report showing solid underlying numbers despite sales being hurt by soft Expert services. $LIME https://www.redeye.se/research/1117639/lime-q2-2025-solid-key-figures-softer-consulting-hurting-sales https://www.redeye.se/research/1117639/lime-q2-2025-solid-key-figures-softer-consulting-hurting-sales" [X Link](https://x.com/Redeye_/status/1943587606299582490) 2025-07-11T08:26Z 14.5K followers, [---] engagements "Redeye comments on XVIVO's major US setback with a period of elevated uncertainty in the US lung market. $XVIVO https://www.redeye.se/research/1117702/xvivo-a-major-us-setback-with-a-period-of-elevated-uncertainty-in-the-us-lung-market https://www.redeye.se/research/1117702/xvivo-a-major-us-setback-with-a-period-of-elevated-uncertainty-in-the-us-lung-market" [X Link](https://x.com/Redeye_/status/1943605714334695518) 2025-07-11T09:38Z 14.5K followers, [----] engagements "Redeye updates its Base Case and forecasts for Lime following the Q2 report. $LIME https://www.redeye.se/research/1117708/lime-breakthrough-among-german-utilities https://www.redeye.se/research/1117708/lime-breakthrough-among-german-utilities" [X Link](https://x.com/Redeye_/status/1944639501789204768) 2025-07-14T06:06Z 14.5K followers, [---] engagements "Redeye provides an update following Iconovos Q2 report. $ICO https://www.redeye.se/research/1117906/iconovo-q2-an-undramatic-report-with-early-signs-of-cost-reductions https://www.redeye.se/research/1117906/iconovo-q2-an-undramatic-report-with-early-signs-of-cost-reductions" [X Link](https://x.com/Redeye_/status/1945002072392298997) 2025-07-15T06:06Z 14.5K followers, [---] engagements "Redeye comments on XVIVOs Q2 revealing an unexpectedly sharp slowdown in its US lung business. The magnitude of the decline coupled with limited near-term visibility came as a surprise not only to investors but also to key customers. $XVIVO https://www.redeye.se/api/articles/download-file/17b1f93f-82ee-34ed-aca2-eaf1356cdf2d/XVIVO%3A%20A%20major%20challenge%20triggers%20a%20major%20opportunity https://www.redeye.se/api/articles/download-file/17b1f93f-82ee-34ed-aca2-eaf1356cdf2d/XVIVO%3A%20A%20major%20challenge%20triggers%20a%20major%20opportunity" [X Link](https://x.com/Redeye_/status/1945026036665606447) 2025-07-15T07:41Z 14.5K followers, [----] engagements "Redeye comments on this morning's press release from Arise stating that it has reached an agreement with Foresight regarding the earn-out payment for Klvallen of approx. EUR30m. $ARISE https://www.redeye.se/research/1118403/arise-eur30m-earn-out-payment-secured https://www.redeye.se/research/1118403/arise-eur30m-earn-out-payment-secured" [X Link](https://x.com/Redeye_/status/1945395532240769448) 2025-07-16T08:10Z 14.5K followers, [----] engagements "Redeye comments on Evolutions Q2-results which were in line with our expectations albeit with slightly softer topline but somewhat stronger profitability. $EVO https://www.redeye.se/research/1118672/evolution-q2-2025-results-as-expected-guidance-reiterated https://www.redeye.se/research/1118672/evolution-q2-2025-results-as-expected-guidance-reiterated" [X Link](https://x.com/Redeye_/status/1945744710322045175) 2025-07-17T07:17Z 14.5K followers, [----] engagements "Redeye comments on OncoZenges recent amendment to its licensing agreement with Molteni Farmaceutici which accelerates EUR550000 in milestone payments to coincide with CTA approval. $ONCOZ https://www.redeye.se/research/1118804/oncozenge-shifts-to-a-fully-european-phase-iii-study https://www.redeye.se/research/1118804/oncozenge-shifts-to-a-fully-european-phase-iii-study" [X Link](https://x.com/Redeye_/status/1945759854041153829) 2025-07-17T08:17Z 14.5K followers, [---] engagements "Redeye comments on CombinedXs Q2 report showing negative growth and lower margins than expected. On the positive note the underlying data looks relatively solid. $CX https://www.redeye.se/research/1118515/combinedx-q2-2025-lower-sales-hurting https://www.redeye.se/research/1118515/combinedx-q2-2025-lower-sales-hurting" [X Link](https://x.com/Redeye_/status/1945823834776477869) 2025-07-17T12:32Z 14.5K followers, [---] engagements "Redeye updates on Evolution post Q2-results which were largely in line with our forecasts. $EVO https://www.redeye.se/research/1119241/evolution-asia-back-to-growth https://www.redeye.se/research/1119241/evolution-asia-back-to-growth" [X Link](https://x.com/Redeye_/status/1946106699149881682) 2025-07-18T07:16Z 14.5K followers, [----] engagements "Redeye provides its first take on Cellavisions Q2 report [----] published this morning. $CEVI https://www.redeye.se/research/1119287/cellavision-q2-2025-first-review-of-the-results https://www.redeye.se/research/1119287/cellavision-q2-2025-first-review-of-the-results" [X Link](https://x.com/Redeye_/status/1946106842435727842) 2025-07-18T07:16Z 14.5K followers, [---] engagements "Redeye comments on Annexins Q2 report and recent events in the company. $ANNX https://www.redeye.se/research/1119256/annexin-q2-positioned-to-advance-dr-study-and-bd-efforts https://www.redeye.se/research/1119256/annexin-q2-positioned-to-advance-dr-study-and-bd-efforts" [X Link](https://x.com/Redeye_/status/1946107404526989457) 2025-07-18T07:18Z 14.5K followers, [---] engagements "Redeye comments on the takeover offer on Bredband2 from Telia Company. $BRE2 https://www.redeye.se/research/1119356/bredband2-takeover-offer-from-telia https://www.redeye.se/research/1119356/bredband2-takeover-offer-from-telia" [X Link](https://x.com/Redeye_/status/1946107626128916792) 2025-07-18T07:19Z 14.5K followers, [----] engagements "Redeye updates on InfraCom following Telias bid for Bredband2 at SEK3.25 per share InfraCom has agreed to tender its shares. $INFRA https://www.redeye.se/research/1119411/infracom-cashing-in-on-telias-bid-for-bredband2 https://www.redeye.se/research/1119411/infracom-cashing-in-on-telias-bid-for-bredband2" [X Link](https://x.com/Redeye_/status/1946108165227008477) 2025-07-18T07:21Z 14.5K followers, [----] engagements "Redeye comments on Arises Q2 report which saw higher production than expected driving the segment's earnings generation. $ARISE https://www.redeye.se/research/1119441/arise-q2-2025-underlying-solid https://www.redeye.se/research/1119441/arise-q2-2025-underlying-solid" [X Link](https://x.com/Redeye_/status/1946147738082480445) 2025-07-18T09:59Z 14.5K followers, [---] engagements "Redeye updates its estimates and fair value range following Arises Q2 report. $ARISE https://www.redeye.se/research/1120283/arise-enters-the-harvesting-period https://www.redeye.se/research/1120283/arise-enters-the-harvesting-period" [X Link](https://x.com/Redeye_/status/1947172986844254209) 2025-07-21T05:53Z 14.5K followers, [---] engagements "Redeye comments on Cellavision's first quarter [----] which saw organic sales growth of 8% with the highest growth in ASEA. $CEVI https://www.redeye.se/research/1119494/cellavision-q2-2025-stable-with-decent-growth https://www.redeye.se/research/1119494/cellavision-q2-2025-stable-with-decent-growth" [X Link](https://x.com/Redeye_/status/1947174977465208899) 2025-07-21T06:01Z 14.5K followers, [----] engagements "Redeye provides its initial take on MedCaps Q2 [----] report which roughly matched our top-line projection and beat our adjusted EBITA estimate. $MCAP https://www.redeye.se/research/1120410/medcap-q2-2025-ebita-beat-thesis-playing-out-as-expected https://www.redeye.se/research/1120410/medcap-q2-2025-ebita-beat-thesis-playing-out-as-expected" [X Link](https://x.com/Redeye_/status/1947902095287308507) 2025-07-23T06:10Z 14.5K followers, [----] engagements "Redeye returns with a more in-depth take on Devyser's Q2 report. $DVYSR https://www.redeye.se/research/1120405/devyser-q2-profitable-from-here-on https://www.redeye.se/research/1120405/devyser-q2-profitable-from-here-on" [X Link](https://x.com/Redeye_/status/1947902570548089305) 2025-07-23T06:12Z 14.5K followers, [----] engagements "Redeye updates its estimates and valuation following MedCaps Q2 [----] report. $MCAP https://www.redeye.se/research/1120433/medcap-q2-2025-the-rise-fall-and-rise-again https://www.redeye.se/research/1120433/medcap-q2-2025-the-rise-fall-and-rise-again" [X Link](https://x.com/Redeye_/status/1947990090635960821) 2025-07-23T12:00Z 14.5K followers, [----] engagements "Redeye comments on Safello announcing a partnership with Marginalen Bank positioning itself as the first crypto broker to offer a comprehensive suite of banking services to its customers. $SFL https://www.redeye.se/research/1120731/safello-a-strategic-leap-into-traditional-finance https://www.redeye.se/research/1120731/safello-a-strategic-leap-into-traditional-finance" [X Link](https://x.com/Redeye_/status/1948627855002198239) 2025-07-25T06:14Z 14.5K followers, [----] engagements "Redeye provides a comment on DalaVinds divestment of Fagersen an onshore wind project of more than 200MW to OX2. $DE https://www.redeye.se/research/1120847/dala-energi-dalavind-divests-fagerasen https://www.redeye.se/research/1120847/dala-energi-dalavind-divests-fagerasen" [X Link](https://x.com/Redeye_/status/1948750578772824486) 2025-07-25T14:21Z 14.5K followers, [---] engagements "Redeye comments on XVIVO's delayed launch being a setback for both XVIVO patients and specialist centers waiting to use the solution. $XVIVO https://www.redeye.se/research/1121170/xvivo-the-european-heart-launch-is-delayed-for-6-12-months https://www.redeye.se/research/1121170/xvivo-the-european-heart-launch-is-delayed-for-6-12-months" [X Link](https://x.com/Redeye_/status/1950164259855294746) 2025-07-29T11:59Z 14.5K followers, [----] engagements "Redeye comments on the partnership with SD Pharma in Spain which will broaden physician reach of Pepaxti. $ONCO https://www.redeye.se/research/1121191/oncopeptides-partnership-can-help-accelerate-spanish-sales https://www.redeye.se/research/1121191/oncopeptides-partnership-can-help-accelerate-spanish-sales" [X Link](https://x.com/Redeye_/status/1950470850869862472) 2025-07-30T08:17Z 14.5K followers, [----] engagements "Redeye gives an initial comment on the Leqembi royalty for Q2 and the presentations from AAIC. $BIOA https://www.redeye.se/research/1121261/bioarctic-solid-q2-royalty-and-further-supporting-data-from-aaic https://www.redeye.se/research/1121261/bioarctic-solid-q2-royalty-and-further-supporting-data-from-aaic" [X Link](https://x.com/Redeye_/status/1951257583332864416) 2025-08-01T12:23Z 14.5K followers, [---] engagements "Redeye leaves its preview of RaySearchs Q2 [----] results due on Friday August [--]. $RAY https://www.redeye.se/research/1121317/raysearch-redeye-q2-2025e-preview https://www.redeye.se/research/1121317/raysearch-redeye-q2-2025e-preview" [X Link](https://x.com/Redeye_/status/1952320844887130545) 2025-08-04T10:48Z 14.5K followers, [----] engagements "Redeye comments briefly on Insplorions recent update on strategic development and ongoing key initiatives. $INSP https://www.redeye.se/research/1121396/insplorion-business-activity-update https://www.redeye.se/research/1121396/insplorion-business-activity-update" [X Link](https://x.com/Redeye_/status/1952978934817251656) 2025-08-06T06:23Z 14.5K followers, [----] engagements "Redeye comments on Avtech announcing a three-year extension to its agreement with Wizz Air significantly expanding the scope of the original contract signed in late [----]. $AVT https://www.redeye.se/research/1121444/avtech-bags-an-upsell-with-wizz-air-expansion https://www.redeye.se/research/1121444/avtech-bags-an-upsell-with-wizz-air-expansion" [X Link](https://x.com/Redeye_/status/1953117177768292518) 2025-08-06T15:33Z 14.5K followers, [----] engagements "Redeye updates on Embracer ahead of Q1-results (due [--] August) where we forecast a slow start to 2025/26E with new few game releases while we expect guidance for the full year to be reiterated. $EMBRAC https://www.redeye.se/research/1121449/embracer-preview-q1-2025-26e-slow-start-to-the-year-expected https://www.redeye.se/research/1121449/embracer-preview-q1-2025-26e-slow-start-to-the-year-expected" [X Link](https://x.com/Redeye_/status/1953347289461740026) 2025-08-07T06:47Z 14.5K followers, [----] engagements "Redeye comments on G5s Q2-results where results were weaker than expected partly driven by USD/SEK while gross margin remained strong owing to continued growth of the G5 Store. $G5EN https://www.redeye.se/research/1121476/g5-entertaiment-q2-2025-continued-soft-topline-development https://www.redeye.se/research/1121476/g5-entertaiment-q2-2025-continued-soft-topline-development" [X Link](https://x.com/Redeye_/status/1953347625727459365) 2025-08-07T06:49Z 14.5K followers, [----] engagements "Redeye provides an update following Optomeds Q2 [----] report. $OPTOMED https://www.redeye.se/research/1121556/optomed-q2-soft-q2-sales-raises-the-stakes-for-h2-recovery https://www.redeye.se/research/1121556/optomed-q2-soft-q2-sales-raises-the-stakes-for-h2-recovery" [X Link](https://x.com/Redeye_/status/1953711488973013152) 2025-08-08T06:54Z 14.5K followers, [---] engagements "Redeye returns with a more in-depth take on Raysearchs Q2 report. $RAY https://www.redeye.se/research/1121657/raysearch-q2-gearing-up-for-more-record-quarters https://www.redeye.se/research/1121657/raysearch-q2-gearing-up-for-more-record-quarters" [X Link](https://x.com/Redeye_/status/1954794118846017928) 2025-08-11T06:36Z 14.5K followers, [----] engagements "Redeye comments on Q2 confirming that Mobergs Terclara is now the market leader in both Sweden and Norway. $MOB https://www.redeye.se/research/1121805/moberg-pharma-q2-teclara-is-the-clear-market-leader-in-both-sweden-and-norway https://www.redeye.se/research/1121805/moberg-pharma-q2-teclara-is-the-clear-market-leader-in-both-sweden-and-norway" [X Link](https://x.com/Redeye_/status/1955167403270197363) 2025-08-12T07:20Z 14.5K followers, [----] engagements "Moberg Pharma is trading below Redeye's Base Case. We spoke with our analyst about Moberg Pharma's choice between direct sales and partner-led distribution the role of internal R&D and more. This is a premium article included in our paid plans from SEK 99/month. $MOB https://www.redeye.se/research/1121700/moberg-pharma-expanding-its-european-otc-footprint https://www.redeye.se/research/1121700/moberg-pharma-expanding-its-european-otc-footprint" [X Link](https://x.com/Redeye_/status/1955190063878361397) 2025-08-12T08:50Z 14.5K followers, [----] engagements "Redeye provides an update after Q2 confirms that Mobergs Terclara is now the market leader in both Sweden and Norway. Consumer marketing activities and a strong channel presence have resulted in high market shares of 44% in Sweden (value) and 43% in Norway (value). $MOB https://www.redeye.se/research/1122178/moberg-pharma-terclara-is-the-market-leader-in-both-sweden-and-norway https://www.redeye.se/research/1122178/moberg-pharma-terclara-is-the-market-leader-in-both-sweden-and-norway" [X Link](https://x.com/Redeye_/status/1955530846787518636) 2025-08-13T07:24Z 14.5K followers, [----] engagements "Redeye comments on Embracers Q1-results which were weaker than expected owing mainly to soft performance in PC/Console. $EMBRAC https://www.redeye.se/research/1122352/embracer-q1-2025-26-soft-q1-and-lowered-guidance https://www.redeye.se/research/1122352/embracer-q1-2025-26-soft-q1-and-lowered-guidance" [X Link](https://x.com/Redeye_/status/1955878890343112964) 2025-08-14T06:27Z 14.5K followers, [----] engagements "Redeye comments on Bredband2s Q2 report which posted marginally stronger performance across the board with stronger sales and lower OPEX. $BRE2 https://www.redeye.se/research/1122373/bredband2-q2-2025-solid-figures-telia-takeover-in-spotlight https://www.redeye.se/research/1122373/bredband2-q2-2025-solid-figures-telia-takeover-in-spotlight" [X Link](https://x.com/Redeye_/status/1955995057376387149) 2025-08-14T14:08Z 14.5K followers, [---] engagements "Top Picks makes an update following a minor change in the portfolio where we are increasing our stake in a bet that has been punished way too much by the market. Top Picks is included in our premium memberships from SEK 349/month. $XVIVO https://www.redeye.se/research/1122369/top-picks-when-the-market-gives-you-lemons-make-lemonade https://www.redeye.se/research/1122369/top-picks-when-the-market-gives-you-lemons-make-lemonade" [X Link](https://x.com/Redeye_/status/1955995297269571952) 2025-08-14T14:09Z 14.5K followers, [----] engagements "Redeye states Safellos Q2 [----] presented top-line headwinds with net sales of SEK130.8m falling 20% short of Redeye Research Estimates. $SFL https://www.redeye.se/research/1122474/safello-q2-2025-continued-headwinds https://www.redeye.se/research/1122474/safello-q2-2025-continued-headwinds" [X Link](https://x.com/Redeye_/status/1956252884296769635) 2025-08-15T07:13Z 14.5K followers, [----] engagements "Redeye notes Safellos headwinds from Q1 continued into Q2 [----] with net sales disappointing resulting in an adjusted EBITDA loss of SEK4.9m. $SFL https://www.redeye.se/research/1122538/safello-navigating-a-critical-crossroads https://www.redeye.se/research/1122538/safello-navigating-a-critical-crossroads" [X Link](https://x.com/Redeye_/status/1957332504173543867) 2025-08-18T06:43Z 14.5K followers, [----] engagements "Redeye comments on Ascelia progressing with the Orviglance application and the company is about to complete the electronic configuration of the file. $ACE https://www.redeye.se/research/1122629/ascelia-pharma-good-us-orviglance-news https://www.redeye.se/research/1122629/ascelia-pharma-good-us-orviglance-news" [X Link](https://x.com/Redeye_/status/1957335224108318738) 2025-08-18T06:54Z 14.5K followers, [----] engagements "Redeye comments on Nitro Games' Q2 [----] report which came in softer than expected both in terms of top line and profitability. $NITRO https://www.redeye.se/research/1121735/nitro-games-q2-2025-softer-than-expected https://www.redeye.se/research/1121735/nitro-games-q2-2025-softer-than-expected" [X Link](https://x.com/Redeye_/status/1957335500253274178) 2025-08-18T06:55Z 14.5K followers, [----] engagements "Redeye provides an update following Nitro Games Q2 [----] report which was softer than expected. $NITRO https://www.redeye.se/research/1121743/nitro-games-rising-uncertainty https://www.redeye.se/research/1121743/nitro-games-rising-uncertainty" [X Link](https://x.com/Redeye_/status/1957692007159087551) 2025-08-19T06:32Z 14.5K followers, [---] engagements "Redeye comments on Gentoo Media ahead of Q2-results (due [--] August) were focus is on margin recovery after unusually soft profitability in Q1 on the back of the regulation in Brazil. $G2MNO https://www.redeye.se/research/1122924/gentoo-media-preview-q2-2025e-margin-recovery-in-focus https://www.redeye.se/research/1122924/gentoo-media-preview-q2-2025e-margin-recovery-in-focus" [X Link](https://x.com/Redeye_/status/1957692134397464728) 2025-08-19T06:32Z 14.5K followers, [---] engagements "Redeye give its comments on Starbreeze's Q2 report; After a strong Q1 report where Payday [--] was included for all PlayStation subscribers creating strong momentum in terms of player engagement our expectations were raised a bit too high. $STAR https://www.redeye.se/research/1122324/starbreeze-q2-2025-weaker-playstation-plus-boost-than-expected https://www.redeye.se/research/1122324/starbreeze-q2-2025-weaker-playstation-plus-boost-than-expected" [X Link](https://x.com/Redeye_/status/1957729316705276171) 2025-08-19T09:00Z 14.5K followers, [---] engagements "Redeye provides an initial take on the Q2 [----] report from Cheffelo which came in slightly below our estimates but in line with what could be expected following the trading update. $CHEF https://www.redeye.se/research/1123058/cheffelo-q2-2025-no-drama https://www.redeye.se/research/1123058/cheffelo-q2-2025-no-drama" [X Link](https://x.com/Redeye_/status/1958068011937489205) 2025-08-20T07:26Z 14.5K followers, [----] engagements "Redeye updates its estimates and valuation following the Q2 [----] report from Cheffelo. $CHEF https://www.redeye.se/research/1123102/cheffelo-momentum-remains-on-the-menu https://www.redeye.se/research/1123102/cheffelo-momentum-remains-on-the-menu" [X Link](https://x.com/Redeye_/status/1958412166312185874) 2025-08-21T06:13Z 14.5K followers, [----] engagements "Redeye provides its initial take on Surgical Sciences Q2 [----] report which aligned with its profit warning and underperformed our original projections across the board. $SUS https://www.redeye.se/research/1123724/surgical-science-q2-2025-in-line-with-profit-warning https://www.redeye.se/research/1123724/surgical-science-q2-2025-in-line-with-profit-warning" [X Link](https://x.com/Redeye_/status/1958412593678242162) 2025-08-21T06:15Z 14.5K followers, [----] engagements "Redeye comments on Ascelias two most important value drivers being the US submission which is now de-risked and Ascelia is expecting a submission in early September. $ACE https://www.redeye.se/research/1123807/ascelia-pharma-just-about-to-submit-orviglance-for-us-approval https://www.redeye.se/research/1123807/ascelia-pharma-just-about-to-submit-orviglance-for-us-approval" [X Link](https://x.com/Redeye_/status/1958438112507695471) 2025-08-21T07:56Z 14.5K followers, [----] engagements "Redeye comments on Starbreeze's weaker-than-expected quarter regarding revenue and profitability; however we are raising our sales estimates for the second half of [----]. $STAR https://www.redeye.se/research/1122420/starbreeze-effect-from-publishing-switch-in-q3 https://www.redeye.se/research/1122420/starbreeze-effect-from-publishing-switch-in-q3" [X Link](https://x.com/Redeye_/status/1958439090036039877) 2025-08-21T08:00Z 14.5K followers, [---] engagements "Redeye updates its estimates following Surgical Sciences Q2 [----] report which aligned with the companys profit warning and broadly underperformed our original projections. $SUS https://www.redeye.se/research/1124019/surgical-science-q2-2025-expect-continued-volatility https://www.redeye.se/research/1124019/surgical-science-q2-2025-expect-continued-volatility" [X Link](https://x.com/Redeye_/status/1958786487329206764) 2025-08-22T07:01Z 14.5K followers, [---] engagements "Redeye notes that InfraComs Q2 [----] report was below expectations for sales (-9%) and EBITDA (-12%). $INFRA https://www.redeye.se/research/1124090/infracom-q2-2025-a-soft-quarter-awaiting-a-sek178m-windfall https://www.redeye.se/research/1124090/infracom-q2-2025-a-soft-quarter-awaiting-a-sek178m-windfall" [X Link](https://x.com/Redeye_/status/1958787328266084624) 2025-08-22T07:04Z 14.5K followers, [----] engagements "Redeye notes that Avtech delivered another solid quarter with net sales growing 37% y/y in line with both preliminary figures and Redeye's estimates. $AVT https://www.redeye.se/research/1124091/avtech-q2-2025-clear-skies-ahead https://www.redeye.se/research/1124091/avtech-q2-2025-clear-skies-ahead" [X Link](https://x.com/Redeye_/status/1958787715014553828) 2025-08-22T07:05Z 14.5K followers, [----] engagements "Redeye provides a research update following the Q2 report recently published by Initiator Pharma. $INIT https://www.redeye.se/research/1124157/initiator-pharma-q2-financed-to-explore-vulvodynia https://www.redeye.se/research/1124157/initiator-pharma-q2-financed-to-explore-vulvodynia" [X Link](https://x.com/Redeye_/status/1958844459589788110) 2025-08-22T10:51Z 14.5K followers, [----] engagements "Redeye provides an update following CLSs Q2 [----] report. We view the report as strong providing confidence in our forecasts and the companys objectives. $CLS https://www.redeye.se/research/1124336/cls-q2-strong-report-that-reinforces-confidence-in-outlook https://www.redeye.se/research/1124336/cls-q2-strong-report-that-reinforces-confidence-in-outlook" [X Link](https://x.com/Redeye_/status/1959874756557025284) 2025-08-25T07:05Z 14.5K followers, [---] engagements "Redeye views InfraComs Q2 [----] results as mixed with a declining top line contrasted by rising EBIT and EBITDA. $INFRA https://www.redeye.se/research/1124537/infracom-a-crucible-of-confidence https://www.redeye.se/research/1124537/infracom-a-crucible-of-confidence" [X Link](https://x.com/Redeye_/status/1959874849402237131) 2025-08-25T07:05Z 14.5K followers, [---] engagements "Redeye argues that AVTECH has delivered another strong report with sales growth of 37% y/y which was in line with the Redeye's estimates. $AVT https://www.redeye.se/research/1124443/avtech-no-room-for-turbulence https://www.redeye.se/research/1124443/avtech-no-room-for-turbulence" [X Link](https://x.com/Redeye_/status/1959874943925063915) 2025-08-25T07:06Z 14.5K followers, [----] engagements "Redeye har interviewed Claus Elsborg Olesen CEO of Initiator Pharma about the recent Q2 report a strengthened cash position and the strategic expansion into vulvodynia. $INIT https://www.redeye.se/research/1124442/initiator-pharma-q225-interview-with-ceo-claus-elsborg-olesen https://www.redeye.se/research/1124442/initiator-pharma-q225-interview-with-ceo-claus-elsborg-olesen" [X Link](https://x.com/Redeye_/status/1959876368591667647) 2025-08-25T07:11Z 14.5K followers, [----] engagements "Redeye gives an initial comment on the positive news that BioArctic has signed an option collaboration and license agreement with Novartis related to its BrainTransporter platform. $BIOA https://www.redeye.se/research/1125081/bioarctic-signs-braintransporter-agreement-with-novartis https://www.redeye.se/research/1125081/bioarctic-signs-braintransporter-agreement-with-novartis" [X Link](https://x.com/Redeye_/status/1960316176585671116) 2025-08-26T12:19Z 14.5K followers, [----] engagements "Redeye has interviewed AVTECH's Chief Executive David Rytter to discuss the company's sales pipeline new product developments and strategic management hires. $AVT https://www.redeye.se/research/1125114/avtech-q225-interview-with-ceo-david-rytter https://www.redeye.se/research/1125114/avtech-q225-interview-with-ceo-david-rytter" [X Link](https://x.com/Redeye_/status/1960592525518856501) 2025-08-27T06:37Z 14.5K followers, [----] engagements "Redeye makes a correction to our estimates slightly impacting our fair value range for CLS. $CLS https://www.redeye.se/research/1125580/cls-correction-to-our-estimates https://www.redeye.se/research/1125580/cls-correction-to-our-estimates" [X Link](https://x.com/Redeye_/status/1960954417504461258) 2025-08-28T06:35Z 14.5K followers, [----] engagements "Redeye initiates coverage of BICO a leading player in the bioconvergence space. $BICO https://www.redeye.se/research/1125575/bico-group-a-forgotten-darling-with-turnaround-potential https://www.redeye.se/research/1125575/bico-group-a-forgotten-darling-with-turnaround-potential" [X Link](https://x.com/Redeye_/status/1960955654182449322) 2025-08-28T06:40Z 14.5K followers, [----] engagements "Redeye comments on Dala Energis Q2 report which was again characterised by the strategic restructuring and voluntary share redemption that took place during the quarter. $DE https://www.redeye.se/research/1126009/dala-energi-q2-2025-progressing-steadily https://www.redeye.se/research/1126009/dala-energi-q2-2025-progressing-steadily" [X Link](https://x.com/Redeye_/status/1961344427743449496) 2025-08-29T08:25Z 14.5K followers, [---] engagements "Redeye is not surprised by Insplorion's announced directed share issue of SEK6m. $INSP https://www.redeye.se/research/1126060/insplorion-q2-2025-initial-comment https://www.redeye.se/research/1126060/insplorion-q2-2025-initial-comment" [X Link](https://x.com/Redeye_/status/1961379322914034035) 2025-08-29T10:44Z 14.5K followers, [----] engagements "Redeye is only making minor changes to our forecasts following Insplorion's Q2 report and other recent events. $INSP https://www.redeye.se/research/1126172/insplorion-large-follow-up-order-in-the-pipeline https://www.redeye.se/research/1126172/insplorion-large-follow-up-order-in-the-pipeline" [X Link](https://x.com/Redeye_/status/1962409437504680301) 2025-09-01T06:57Z 14.5K followers, [----] engagements "Redeye updates its estimates and fair value range following Dala Energis Q2 report that was released last Friday. $DE https://www.redeye.se/research/1126285/dala-energi-all-eyes-on-the-nav https://www.redeye.se/research/1126285/dala-energi-all-eyes-on-the-nav" [X Link](https://x.com/Redeye_/status/1962784147216244809) 2025-09-02T07:46Z 14.5K followers, [----] engagements "RaySearch Laboratories is trading below Redeyes Base Case. We spoke our analyst about the companys plans to defend market share its vulnerability to further order delays and more. This is a premium article included in our paid plans from SEK 99/month. $RAY https://www.redeye.se/research/1126114/raysearch-laboratories-optimising-cancer-care-through-software https://www.redeye.se/research/1126114/raysearch-laboratories-optimising-cancer-care-through-software" [X Link](https://x.com/Redeye_/status/1962790245524521059) 2025-09-02T08:10Z 14.5K followers, [----] engagements "Redeye comments on Ascelia submitting Orviglance to the FDA. The next step is to start the initial filing review process with an FDA confirmation within [--] days from submission. $ACE https://www.redeye.se/research/1126475/ascelia-pharma-a-timely-fda-submission-with-an-extended-cash-runway https://www.redeye.se/research/1126475/ascelia-pharma-a-timely-fda-submission-with-an-extended-cash-runway" [X Link](https://x.com/Redeye_/status/1963180778428256494) 2025-09-03T10:02Z 14.5K followers, [----] engagements "Redeye comments on Initiator Pharmas announcement that it has submitted a CTA to the UK authorities for a phase IIa proof-of-concept study of pudafensine in vulvodynia. $INIT https://www.redeye.se/research/1126541/initiator-pharma-cta-submitted-for-phase-iia-study-in-vulvodynia https://www.redeye.se/research/1126541/initiator-pharma-cta-submitted-for-phase-iia-study-in-vulvodynia" [X Link](https://x.com/Redeye_/status/1963242276391469383) 2025-09-03T14:06Z 14.5K followers, [----] engagements "Redeye is positive about the FDA clearance to expand the labeling of the Prism system. $CLS https://www.redeye.se/research/1126769/cls-fda-clearance-for-1-5t-mri-guidance https://www.redeye.se/research/1126769/cls-fda-clearance-for-1-5t-mri-guidance" [X Link](https://x.com/Redeye_/status/1963843676041355341) 2025-09-05T05:56Z 14.5K followers, [----] engagements "🏆 And the winner is As part of our Q225 Microcap Report we hosted a summer case pitching competition. The winning pitch is now featured in the report - but you can also read all submitted cases on our new #MicrocapCollective https://mcc.redeye.se https://mcc.redeye.se" [X Link](https://x.com/Redeye_/status/1965293588465811884) 2025-09-09T05:57Z 14.5K followers, [----] engagements "Redeye return with a research update following BioArctic's Q2 and latest newsflow. $BIOA https://www.redeye.se/research/1126101/bioarctic-strong-momentum-fair-price https://www.redeye.se/research/1126101/bioarctic-strong-momentum-fair-price" [X Link](https://x.com/Redeye_/status/1965299976608923941) 2025-09-09T06:23Z 14.5K followers, [----] engagements "Redeye has updated the NGR figures for May based on data from the tax authority where the overall NGR was up 5% Y/Y and up 2% M/M. This is a premium article included in our paid plans from SEK 99/month. https://www.redeye.se/research/1128542/net-gaming-revenues-in-the-swedish-online-gambling-sector-may-7https://www.redeye.se/research/1128542/net-gaming-revenues-in-the-swedish-online-gambling-sector-may-7" [X Link](https://x.com/Redeye_/status/1970391653992296745) 2025-09-23T07:35Z 14.5K followers, [---] engagements "Redeye comments on Ascelia raising around SEK30m in a directed share issue - we see this as a sign of strength and give our initial take. $ACE https://www.redeye.se/research/1128559/ascelia-pharma-sek30m-raised-in-a-directed-share-issue https://www.redeye.se/research/1128559/ascelia-pharma-sek30m-raised-in-a-directed-share-issue" [X Link](https://x.com/Redeye_/status/1970391905939718408) 2025-09-23T07:36Z 14.5K followers, [----] engagements "Redeye comments on todays news from Cheffelo where financial targets have been raised ahead of its now scheduled CMD. $CHEF https://www.redeye.se/research/1128667/cheffelo-raising-the-steaks https://www.redeye.se/research/1128667/cheffelo-raising-the-steaks" [X Link](https://x.com/Redeye_/status/1970748228053144046) 2025-09-24T07:12Z 14.5K followers, [----] engagements "Redeye has interviewed Magnus Corfitzen CEO of Ascelia Pharma regarding recent positive newsflow; including the NDA submission to FDA for Orviglance and a directed share issue of SEK 30m. $ACE https://www.redeye.se/research/1128911/ascelia-pharma-interview-with-ceo-magnus-corfitzen-4 https://www.redeye.se/research/1128911/ascelia-pharma-interview-with-ceo-magnus-corfitzen-4" [X Link](https://x.com/Redeye_/status/1971504245259313517) 2025-09-26T09:16Z 14.5K followers, [----] engagements "Redeye leaves a short comment on CLSs fully subscribed warrants program (TO8B). $CLS https://www.redeye.se/research/1129114/cls-fully-subscribed-to8b-program-as-expected https://www.redeye.se/research/1129114/cls-fully-subscribed-to8b-program-as-expected" [X Link](https://x.com/Redeye_/status/1973275376693682680) 2025-10-01T06:34Z 14.5K followers, [---] engagements "Redeye Investor Forum Online last out [-----] Elicera Therapeutics Jamal El Mosleh CEO [-----] Ferroamp William Ryan CFO [-----] Climeon Lena Sundquist CEO Tune in: https://www.redeye.se/events/1109578/investor-forum-online-38tab=schedule https://www.redeye.se/events/1109578/investor-forum-online-38tab=schedule" [X Link](https://x.com/Redeye_/status/1973736473712345449) 2025-10-02T13:07Z 14.5K followers, [---] engagements "Redeye is positive about the results from CLSs study at Skne University Hospital. $CLS https://www.redeye.se/research/1129930/cls-solid-results-from-sus-study https://www.redeye.se/research/1129930/cls-solid-results-from-sus-study" [X Link](https://x.com/Redeye_/status/1975862558377820172) 2025-10-08T09:55Z 14.5K followers, [---] engagements "Physitrack is trading below Redeye's Base Case. We spoke with our analyst regarding the the current expectations for the following report Physitrack's strategy to convert the Nexa/Physitrack partnership into broader Wellness traction and other key topics. This is a premium article included in our paid plans from SEK 99/month. $PTRK https://www.redeye.se/research/1130285/physitrack https://www.redeye.se/research/1130285/physitrack" [X Link](https://x.com/Redeye_/status/1978012890620690727) 2025-10-14T08:19Z 14.5K followers, [---] engagements "#tech #growth Imponerande bolag under kraftig tillvxt se video p $HTRO $POLYG $LEO $NEON http://beta.redeye.se/member/dashboard/all-companies/502310/techbolag-med-imponerande-tillvaxt/members_content http://beta.redeye.se/member/dashboard/all-companies/502310/techbolag-med-imponerande-tillvaxt/members_content" [X Link](https://x.com/Redeye_/status/776091143259971584) 2016-09-14T16:12Z 14.5K followers, [--] engagements "No drama in @Heliospectra balance sheet for liquidation purposes is a formality notes Joel Westerstrm @Qwertyrius http://beta.redeye.se/company/heliospectra/506381/no-drama-heliospectra-s-announcement-it-will-prepare-balance-sheet-liquidation-purposes#company-navigation http://beta.redeye.se/company/heliospectra/506381/no-drama-heliospectra-s-announcement-it-will-prepare-balance-sheet-liquidation-purposes#company-navigation" [X Link](https://x.com/Redeye_/status/786913165854605313) 2016-10-14T12:54Z 14.7K followers, [--] engagements "$NUE We have now initiated analyst coverage of #Nuevolution - Read the first analysis by Mathias Spinnars at: http://beta.redeye.se/company/nuevolution/531509/nuevolution-nue-hope-drug-discovery#company-navigation http://beta.redeye.se/company/nuevolution/531509/nuevolution-nue-hope-drug-discovery#company-navigation" [X Link](https://x.com/Redeye_/status/847333992005115908) 2017-03-30T06:25Z 14.7K followers, [--] engagements "$FPIP Steady growth in recurring revenues in @Formpipe during Q1 Johan Svantesson comments: http://beta.redeye.se/company/formpipe-software/535018/formpipe-q1-comment-steady-growth-recurring-revenues#company-navigation http://beta.redeye.se/company/formpipe-software/535018/formpipe-q1-comment-steady-growth-recurring-revenues#company-navigation" [X Link](https://x.com/Redeye_/status/856448000612339712) 2017-04-24T10:01Z 14.5K followers, [--] engagements "$IMINT We are expecting an exciting [----] for #IMINT - download our new analysis at: http://beta.redeye.se/company/imint-image-intelligence/535049/imint-expecting-exciting-2017 http://beta.redeye.se/company/imint-image-intelligence/535049/imint-expecting-exciting-2017" [X Link](https://x.com/Redeye_/status/856483710882938880) 2017-04-24T12:23Z 14.5K followers, [--] engagements "Increased profitability in @Formpipe $FPIP leads to Johan Svantesson raising our fair value range in his update: http://beta.redeye.se/company/formpipe-software/539120/formpipe-continues-increase-profitability#company-navigation http://beta.redeye.se/company/formpipe-software/539120/formpipe-continues-increase-profitability#company-navigation" [X Link](https://x.com/Redeye_/status/857853448439705600) 2017-04-28T07:06Z 14.5K followers, [--] engagements "$ANOD Our analyst Kristoffer Lindstrm @Lindstroem_K has published an updated analysis of #AddnodeGroup. Read it at: http://beta.redeye.se/company/addnode-group/540323/addnode-group-new-market-region#company-navigation http://beta.redeye.se/company/addnode-group/540323/addnode-group-new-market-region#company-navigation" [X Link](https://x.com/Redeye_/status/860076178484453376) 2017-05-04T10:18Z 14.5K followers, [--] engagements "New agreement with large Chinese manufacturer signed by $IMINT @vidhance confirming Dennis Berggren's view on case: http://beta.redeye.se/company/imint-image-intelligence/545266/imint-signs-development-agreement-chinese-smartphone-producer http://beta.redeye.se/company/imint-image-intelligence/545266/imint-signs-development-agreement-chinese-smartphone-producer" [X Link](https://x.com/Redeye_/status/870642029977628673) 2017-06-02T14:03Z 14.5K followers, [--] engagements "#Formpipe will release their Q2 report on Friday. Take part of our expectations here: $FPIP https://www.redeye.se/company/formpipe-software/550376/formpipe-q2-preview#company-navigation https://www.redeye.se/company/formpipe-software/550376/formpipe-q2-preview#company-navigation" [X Link](https://x.com/Redeye_/status/885054903026167808) 2017-07-12T08:35Z 14.5K followers, [--] engagements "Q2 comment @Formpipe: More SaaS affects earnings in the short term. Read our comment here: $FPIP https://www.redeye.se/company/formpipe-software/550775/formpipe-q2-comment-more-saas-affects-earnings-short-term#company-navigation https://www.redeye.se/company/formpipe-software/550775/formpipe-q2-comment-more-saas-affects-earnings-short-term#company-navigation" [X Link](https://x.com/Redeye_/status/885787492410150912) 2017-07-14T09:06Z 14.5K followers, [--] engagements "$FPIP Increase in SaaS deliveries affected Q2 negatively in @Formpipe - positive with +8% recurring revenues Y/Y: https://www.redeye.se/company/formpipe-software/551428/formpipe-increase-saas-deliveries-affected-q2-negatively https://www.redeye.se/company/formpipe-software/551428/formpipe-increase-saas-deliveries-affected-q2-negatively" [X Link](https://x.com/Redeye_/status/887918118634491904) 2017-07-20T06:12Z 14.5K followers, [--] engagements "Expectations of Q2 - #Imint. We expect net revenues to come in about SEK 3.6m and EBIT around SEK -2.1m. $IMINT https://www.redeye.se/company/imint-image-intelligence/554729/imint-expectations-q2#company-navigation https://www.redeye.se/company/imint-image-intelligence/554729/imint-expectations-q2#company-navigation" [X Link](https://x.com/Redeye_/status/899530174634622977) 2017-08-21T07:14Z 14.5K followers, [--] engagements "Q2 Sales higher than expected - #Imint. Dennis Berggren gives his first comment. @vidhance $IMINT https://www.redeye.se/company/imint-image-intelligence/554907/imint-q2-sales-higher-expected#company-navigation https://www.redeye.se/company/imint-image-intelligence/554907/imint-q2-sales-higher-expected#company-navigation" [X Link](https://x.com/Redeye_/status/899957064180670465) 2017-08-22T11:30Z 14.5K followers, [--] engagements "$FPIP: EBIT and the EBIT-margin were better than our expectations - @Formpipe. Read our report comment: https://www.redeye.se/company/formpipe-software/566852/formpipe-stable-growth-recurring-revenuesutm_medium=RSS&utm_source=redeye https://www.redeye.se/company/formpipe-software/566852/formpipe-stable-growth-recurring-revenuesutm_medium=RSS&utm_source=redeye" [X Link](https://x.com/Redeye_/status/923564268674600961) 2017-10-26T14:57Z 14.5K followers, [--] engagements "First comment - $IMINT. "We had expected a somewhat stronger quarter." writes our analyst Dennis Berggren https://www.redeye.se/company/imint-image-intelligence/579334/imint-no-major-surprises https://www.redeye.se/company/imint-image-intelligence/579334/imint-no-major-surprises" [X Link](https://x.com/Redeye_/status/966978062381469696) 2018-02-23T10:08Z 14.5K followers, [--] engagements Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing
@Redeye_ Redeye
Redeye posts on X about ceo, comments, $avt, strong the most. They currently have [------] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.
Engagements: [---] #
- [--] Week [------] +56%
- [--] Month [------] +60%
- [--] Months [-------] -23%
- [--] Year [---------] -11%
Mentions: [--] #
- [--] Week [--] +85%
- [--] Month [---] -1.70%
- [--] Months [-----] -3.40%
- [--] Year [-----] +55%
Followers: [------] #
- [--] Week [------] no change
- [--] Month [------] -0.14%
- [--] Months [------] -0.52%
- [--] Year [------] -1.30%
CreatorRank: [---------] #
Social Influence
Social category influence cryptocurrencies 23.28% finance 7.41% stocks 6.35% exchanges 3.17% countries 2.65% gaming 0.53%
Social topic influence ceo 4.76%, comments 4.23%, $avt #7, strong 3.7%, $ace 3.17%, ace 3.17%, $fpip 3.17%, $lagr 2.65%, $htro 2.65%, growth 2.65%
Top accounts mentioned or mentioned by @formpipe @vidhance @heliospectra @qwertyrius @lindstroemk @mrchaarless
Top assets mentioned Aventus (AVT) Fusionist (ACE) Raydium (RAY) Coldstack (CLS) Evotec SE (EVO) BioAge Labs, Inc. (BIOA) Inspect (INSP) iMe Lab (LIME) Cemex S.A.B. de C.V. (CX) Bware (INFRA) Deere & Company (DE) MobileCoin (MOB) Initia (INIT) Annexon, Inc. (ANNX) Nitro League (NITRO) Starbase (STAR)
Top Social Posts
Top posts by engagements in the last [--] hours
"Redeye considers I-Tech's Q4 report to be soft although the company faced relatively high set expectations and tough comps. $ITECH https://www.redeye.se/research/1146854/i-tech-q4-initial-take-softer-than-expected-top-line https://www.redeye.se/research/1146854/i-tech-q4-initial-take-softer-than-expected-top-line"
X Link 2026-02-05T09:07Z 14.4K followers, [---] engagements
"Redeye har intervjuat I-Techs vd Markus Jnsson angende Q4 rapporten. $ITECH https://www.redeye.se/research/1147207/i-tech-q4-intervju-redeye-pratar-med-vd-markus-jonsson https://www.redeye.se/research/1147207/i-tech-q4-intervju-redeye-pratar-med-vd-markus-jonsson"
X Link 2026-02-06T14:00Z 14.4K followers, [---] engagements
"Redeye comments on Tradedoubler's Q4 report showcasing solid underlying execution in a cautious market environment. $TRAD https://www.redeye.se/research/1143262/tradedoubler-q4-review-double-digit-metapic-single-digit-multiple https://www.redeye.se/research/1143262/tradedoubler-q4-review-double-digit-metapic-single-digit-multiple"
X Link 2026-02-13T09:01Z 14.4K followers, [---] engagements
"Redeye notes that Devyser delivered sales relatively in line with expectations but the star of the show was the excellent EBIT margin of 25% thanks to continued impressive cost control and returning Thermo Fisher sales. $DVYSR https://www.redeye.se/research/1149851/devyser-diagnostics-q4-review-jaw-dropping-ebit-margin https://www.redeye.se/research/1149851/devyser-diagnostics-q4-review-jaw-dropping-ebit-margin"
X Link 2026-02-13T09:06Z 14.4K followers, [---] engagements
"Redeye comments on Annexins Q4 report and recent events and see good initial progress in the phase II study. $ANNX https://www.redeye.se/research/1147539/annexin-pharmaceuticals-q4-review-phase-ii-study-away-with-positive-initial-results https://www.redeye.se/research/1147539/annexin-pharmaceuticals-q4-review-phase-ii-study-away-with-positive-initial-results"
X Link 2026-02-06T13:57Z 14.4K followers, [---] engagements
"Redeye comments on Active Biotech's fourth quarter report. $ACTI https://www.redeye.se/research/1150157/active-biotech-q4-review-tasqinimod-recruiting-again https://www.redeye.se/research/1150157/active-biotech-q4-review-tasqinimod-recruiting-again"
X Link 2026-02-13T11:10Z 14.4K followers, [---] engagements
"Redeye's view of Genovis Q2 report is balanced sales were largely in line but profitability was softer than we had estimated. $GENO http://redeye.se/research/1121748/genovis-q2-2025-initial-comments http://redeye.se/research/1121748/genovis-q2-2025-initial-comments"
X Link 2025-08-12T08:49Z 14.4K followers, [----] engagements
"Redeye notes an interesting press release from Genovis confirming a SEK11m order from a global pharmaceutical company. $GENO https://www.redeye.se/research/1131032/genovis-eur1m-order-strengthening-the-outlook https://www.redeye.se/research/1131032/genovis-eur1m-order-strengthening-the-outlook"
X Link 2025-10-20T05:00Z 14.4K followers, [----] engagements
"Redeye provides an initial comment on the Q3 [----] report from Sdiptech where adjusted EBITA came in exactly in line with our forecasts although stronger than consensus. $SDIP https://www.redeye.se/research/1132080/sdiptech-q3-initial-take-adj-ebita-in-line-with-estimates https://www.redeye.se/research/1132080/sdiptech-q3-initial-take-adj-ebita-in-line-with-estimates"
X Link 2025-10-24T06:58Z 14.4K followers, [---] engagements
"Redeye has interviewed Lagercrantzs CEO Jrgen Wigh. $LAGR https://www.redeye.se/research/1132817/lagercrantz-q2-interview-redeye-speaks-with-ceo-jorgen-wigh https://www.redeye.se/research/1132817/lagercrantz-q2-interview-redeye-speaks-with-ceo-jorgen-wigh"
X Link 2025-10-24T11:32Z 14.4K followers, [---] engagements
"Redeye updates its estimates and valuation after Lagercrantzs Q2 2025/2026 report. $LAGR https://www.redeye.se/research/1133217/lagercrantz-q3-review-strong-ma-pipeline https://www.redeye.se/research/1133217/lagercrantz-q3-review-strong-ma-pipeline"
X Link 2025-10-27T08:52Z 14.4K followers, [---] engagements
"Redeye reviews SynAct Pharma's Q3 report. $SYNACT https://www.redeye.se/research/1133751/synact-q3-update-advance-approaching-full-recruitment https://www.redeye.se/research/1133751/synact-q3-update-advance-approaching-full-recruitment"
X Link 2025-10-31T07:35Z 14.4K followers, [---] engagements
"Hexatronic is trading below Redeyes Base Case. We spoke with our analyst about the stronger-than-expected momentum in the Data Center segment main sources of income and other key topics. This is a premium article included in our paid plans from SEK 99/month. $HTRO https://www.redeye.se/research/1138115/hexatronic https://www.redeye.se/research/1138115/hexatronic"
X Link 2025-11-11T09:16Z 14.4K followers, [----] engagements
"Redeye takes a positive stance towards Vertiseits acquisition of Muse expanding the offering into a new related area which is going through a major transformation. $VERT https://www.redeye.se/research/1140069/vertiseit-entering-audio-as-ai-transforms-the-market https://www.redeye.se/research/1140069/vertiseit-entering-audio-as-ai-transforms-the-market"
X Link 2025-11-20T14:00Z 14.4K followers, [---] engagements
"Vitrolife is trading below Redeyes Bear Case. We spoke with our analyst about what drives Vitrolife's competitive position in the global IVF market how sustainable gross margins above 60% are in core segments and other key topics. This is a premium article included in our paid plans from SEK 99/month. $VITR https://www.redeye.se/research/1146054/vitrolife https://www.redeye.se/research/1146054/vitrolife"
X Link 2026-01-27T09:17Z 14.4K followers, [---] engagements
"Redeye comments on Avtech releasing their preliminary figures for Q4 [----] which fell short of Redeye expectations on both sales and EBITDA. $AVT https://www.redeye.se/research/1146122/avtech-q4-preliminary-figures-sales-miss-due-to-postponed-sales https://www.redeye.se/research/1146122/avtech-q4-preliminary-figures-sales-miss-due-to-postponed-sales"
X Link 2026-01-27T13:50Z 14.4K followers, [----] engagements
"Redeye provides its initial take on Indutrades Q4 [----] report which missed on earnings mainly due to two relatively large project write-downs in the UK. $INDT https://www.redeye.se/research/1146294/indutrade-q4-initial-take-project-write-downs-hurt-ebita https://www.redeye.se/research/1146294/indutrade-q4-initial-take-project-write-downs-hurt-ebita"
X Link 2026-01-29T17:38Z 14.4K followers, [---] engagements
"Redeye provides its initial take on Lifcos Q4 [----] report which missed our projections by 3% on sales and 5% on EBITA. $LIFCO https://www.redeye.se/research/1146457/lifco-q4-initial-take-slight-miss-driven-by-dental-and-demolition-tools https://www.redeye.se/research/1146457/lifco-q4-initial-take-slight-miss-driven-by-dental-and-demolition-tools"
X Link 2026-02-02T06:00Z 14.4K followers, [---] engagements
"Redeye comments on Vitrolifes Q4 report coming in very close to our projections reflecting modest underlying growth and a significant reported EBIT loss driven by the goodwill impairment announced in December. $VITR https://www.redeye.se/research/1145964/vitrolife-q4-initial-take-aligned-nicely-with-estimates https://www.redeye.se/research/1145964/vitrolife-q4-initial-take-aligned-nicely-with-estimates"
X Link 2026-02-03T08:48Z 14.4K followers, [---] engagements
"Redeye has interviewed SynAct Pharma's CSO Thomas Jonassen about a new investigator-sponsored phase II study of resomelagon in viral infections. $SYNACT https://www.redeye.se/research/1146848/synact-pharma-interview-redeye-speaks-with-cso-thomas-jonassen https://www.redeye.se/research/1146848/synact-pharma-interview-redeye-speaks-with-cso-thomas-jonassen"
X Link 2026-02-03T13:17Z 14.4K followers, [---] engagements
"Redeye updates its estimates and valuation after Lifcos Q4 [----] report. $LIFCO https://www.redeye.se/research/1146626/lifco-q4-review-steady-as-she-goes https://www.redeye.se/research/1146626/lifco-q4-review-steady-as-she-goes"
X Link 2026-02-04T08:01Z 14.4K followers, [---] engagements
"Redeye comments on the current valuation profile of Vitrolife requiring more than the current stagnant growth profile yesterdays 20% sell-off (despite a report largely in line with Redeyes estimates) appears excessive. $VITR https://www.redeye.se/research/1140910/vitrolife-q4-review-excessive-selloff-improves-risk-reward-in-the-stock https://www.redeye.se/research/1140910/vitrolife-q4-review-excessive-selloff-improves-risk-reward-in-the-stock"
X Link 2026-02-04T08:02Z 14.4K followers, [---] engagements
"Redeye comments on Smart Eyes acquisition of Sightic which removes the most meaningful competitive threat in camera-based alcohol impairment detection and positions the company to dominate what we believe will become a standard safety feature layered on top of DMS. $SEYE https://www.redeye.se/research/1147199/smart-eye-checkmate-on-drunk-driving https://www.redeye.se/research/1147199/smart-eye-checkmate-on-drunk-driving"
X Link 2026-02-05T08:10Z 14.4K followers, [---] engagements
"Redeye comments on Hexatronics Q4 report showing solid overall numbers driven by a further acceleration in Data Center. $HTRO https://www.redeye.se/research/1146077/hexatronic-q4-initial-take-strong-adjusted-numbers-accelerating-growth-in-data-center https://www.redeye.se/research/1146077/hexatronic-q4-initial-take-strong-adjusted-numbers-accelerating-growth-in-data-center"
X Link 2026-02-05T08:12Z 14.4K followers, [---] engagements
"Redeye comments on Evolutions Q4-results which were close to our forecasts albeit with soft revenue in Europe while LatAm and Asia were slightly stronger than expected. $EVO https://www.redeye.se/research/1147410/evolution-q4-initial-take-close-to-our-expectations https://www.redeye.se/research/1147410/evolution-q4-initial-take-close-to-our-expectations"
X Link 2026-02-05T08:14Z 14.4K followers, [----] engagements
"Redeye comments on Fractal Gaming Groups Q4 [----] report which came in below our expectations. $FRACTL https://www.redeye.se/research/1145586/fractal-q4-initial-take-tough-macro-weighs-on-profitability https://www.redeye.se/research/1145586/fractal-q4-initial-take-tough-macro-weighs-on-profitability"
X Link 2026-02-05T08:14Z 14.4K followers, [---] engagements
"Redeye has interviewed Hexatronic's CEO Rikard Frberg about the fourth quarter and how the company manages to growth fast within Data Center. $HTRO https://www.redeye.se/research/1147202/hexatronic-q4-interview-redeye-speaks-with-ceo-rikard-froberg https://www.redeye.se/research/1147202/hexatronic-q4-interview-redeye-speaks-with-ceo-rikard-froberg"
X Link 2026-02-05T09:08Z 14.4K followers, [---] engagements
"Redeye presents its preview of RaySearchs Q4 [----] results due on February [--]. $RAY https://www.redeye.se/research/1147593/raysearch-q4-preview-possibilities-for-a-beaming-end-to-2025 https://www.redeye.se/research/1147593/raysearch-q4-preview-possibilities-for-a-beaming-end-to-2025"
X Link 2026-02-05T12:57Z 14.4K followers, [---] engagements
"Redeye updates on Evolution post Q4-results which were close to our forecasts while the companys margin guidance for [----] was also in line with expectations. $EVO https://www.redeye.se/research/1147724/evolution-q4-review-asia-and-europe-continue-to-hold-back-growth https://www.redeye.se/research/1147724/evolution-q4-review-asia-and-europe-continue-to-hold-back-growth"
X Link 2026-02-06T08:26Z 14.4K followers, [----] engagements
"Redeye comments on Vitecs Q4 report. $VIT https://www.redeye.se/research/1146086/vitec-q4-initial-take-clearly-beating-modest-expectations https://www.redeye.se/research/1146086/vitec-q4-initial-take-clearly-beating-modest-expectations"
X Link 2026-02-06T08:27Z 14.4K followers, [---] engagements
"Redeye provides its initial take on CTEKs Q4 numbers where sales were slightly lower than expected but profitability greatly exceeded our expectations. $CTEK https://www.redeye.se/research/1147826/ctek-q4-initial-take-higher-profit-levels-than-expected https://www.redeye.se/research/1147826/ctek-q4-initial-take-higher-profit-levels-than-expected"
X Link 2026-02-06T08:28Z 14.4K followers, [---] engagements
"Redeye provides its initial take on Lagercrantzs Q3 2025/2026 report which showed strong EBITA growth of 20% y/y beating our forecast by 5%. $LAGR https://www.redeye.se/research/1147841/lagercrantz-q3-initial-take-strong-numbers-raised-ambition https://www.redeye.se/research/1147841/lagercrantz-q3-initial-take-strong-numbers-raised-ambition"
X Link 2026-02-06T08:30Z 14.4K followers, [---] engagements
"Redeye takes a slightly more positive view following Hexatronic's Q4 report showing even stronger momentum in Data Center. $HTRO https://www.redeye.se/research/1146071/hexatronic-q4-review-in-good-shape-for-2026 https://www.redeye.se/research/1146071/hexatronic-q4-review-in-good-shape-for-2026"
X Link 2026-02-06T14:01Z 14.4K followers, [---] engagements
"Redeye comments on Fractals share price falling sharply as the market prices in prolonged weakness in PC demand and elevated uncertainty around profitability in [----]. $FRACTL https://www.redeye.se/research/1145688/fractal-gaming-group-q4-review-patience-will-be-rewarded https://www.redeye.se/research/1145688/fractal-gaming-group-q4-review-patience-will-be-rewarded"
X Link 2026-02-06T14:03Z 14.4K followers, [---] engagements
"Redeye strengthens its positive view of Vitec following the Q4 report. $VIT https://www.redeye.se/research/1146081/vitec-q4-review-solid-operations-and-acquisitions-as-usual-in-ai-driven-market-volatility https://www.redeye.se/research/1146081/vitec-q4-review-solid-operations-and-acquisitions-as-usual-in-ai-driven-market-volatility"
X Link 2026-02-09T08:57Z 14.4K followers, [---] engagements
"Redeye har intervjuat CTEKs vd Henrik Fagrenius efter fredagens Q4-rapport som visade lgre omsttning jmfrt med fregende r men en kraftigt frbttrad lnsamhet och ett starkt kassaflde. $CTEK https://www.redeye.se/research/1147995/ctek-q4-intervju-redeye-pratar-med-vd-henrik-fagrenius https://www.redeye.se/research/1147995/ctek-q4-intervju-redeye-pratar-med-vd-henrik-fagrenius"
X Link 2026-02-09T09:01Z 14.4K followers, [---] engagements
"Redeye updates its estimates and valuation after Lagercrantzs Q3 2025/2026 report. $LAGR https://www.redeye.se/research/1148071/lagercrantz-q3-review-demand-is-picking-up https://www.redeye.se/research/1148071/lagercrantz-q3-review-demand-is-picking-up"
X Link 2026-02-09T09:03Z 14.4K followers, [---] engagements
"Redeye briefly comments on BioArctic's Q4 royalties for Leqembi which came in roughly as expected. $BIOA https://www.redeye.se/research/1147992/bioarctic-q4-royalties-roughly-in-line https://www.redeye.se/research/1147992/bioarctic-q4-royalties-roughly-in-line"
X Link 2026-02-09T09:05Z 14.4K followers, [---] engagements
"Redeye has interviewed Fractal Gaming Groups CEO Jonas Holst who shares key insights from the Q4 report the current market environment and how the category expansion is unfolding. $FRACTL https://www.redeye.se/research/1147991/fractal-gaming-group-q4-interview-redeye-speaks-with-ceo-jonas-holst https://www.redeye.se/research/1147991/fractal-gaming-group-q4-interview-redeye-speaks-with-ceo-jonas-holst"
X Link 2026-02-09T09:06Z 14.4K followers, [---] engagements
"Redeye has interviewed Lagercrantzs CEO Jrgen Wigh. $LAGR https://www.redeye.se/research/1148227/lagercrantz-q3-interview-redeye-speaks-with-ceo-jorgen-wigh https://www.redeye.se/research/1148227/lagercrantz-q3-interview-redeye-speaks-with-ceo-jorgen-wigh"
X Link 2026-02-09T15:25Z 14.4K followers, [---] engagements
"Redeye returns with an update following Ascelia Pharma's Q4 update which contained no material surprises. $ACE https://www.redeye.se/research/1148258/ascelia-pharma-q4-review-on-the-path-to-approval https://www.redeye.se/research/1148258/ascelia-pharma-q4-review-on-the-path-to-approval"
X Link 2026-02-10T08:44Z 14.4K followers, [---] engagements
"Redeye provides an initial comment on the Q4 [----] report from Sdiptech where adjusted EBITA in core operations came in exactly in line with our forecasts and consensus. $SDIP https://www.redeye.se/research/1148192/sdiptech-q4-initial-take-divestments-are-progressing-adj-ebita-in-line https://www.redeye.se/research/1148192/sdiptech-q4-initial-take-divestments-are-progressing-adj-ebita-in-line"
X Link 2026-02-10T08:45Z 14.4K followers, [---] engagements
"Redeye updates its view following CTEKs Q4 report. $CTEK https://www.redeye.se/research/1148634/ctek-q4-review-2026-a-harvesting-year-for-product-investments https://www.redeye.se/research/1148634/ctek-q4-review-2026-a-harvesting-year-for-product-investments"
X Link 2026-02-11T08:56Z 14.4K followers, [---] engagements
"Redeye provides a research update after Optomeds Q4 [----] report. $OPTOMED https://www.redeye.se/research/1148555/optomed-q4-review-devices-segment-growth-supports-outlook-despite-cautious-guidance https://www.redeye.se/research/1148555/optomed-q4-review-devices-segment-growth-supports-outlook-despite-cautious-guidance"
X Link 2026-02-11T08:56Z 14.4K followers, [---] engagements
"Redeye updates its estimates and valuation following MedCaps Q4 [----] report. $MCAP https://www.redeye.se/research/1148546/medcap-q4-review-beat-on-solid-organic-growth https://www.redeye.se/research/1148546/medcap-q4-review-beat-on-solid-organic-growth"
X Link 2026-02-11T08:57Z 14.4K followers, [---] engagements
"Redeye has interviewed Gapwaves' CEO Jonas Ehinger to unpack a strong Q4 rapidly increasing volumes and what the transition to manufacturing partner Frencken means for margins and the path to profitability. $GAPW https://www.redeye.se/research/1148262/gapwaves-q4-interview-redeye-speaks-with-ceo-jonas-ehinger https://www.redeye.se/research/1148262/gapwaves-q4-interview-redeye-speaks-with-ceo-jonas-ehinger"
X Link 2026-02-11T08:58Z 14.4K followers, [---] engagements
"Redeye updates on EG7 ahead of Q4-results (due [--] February) where we expect the results to remain largely stable compared to Q3 as currency headwind counteracts positive seasonality. $EG7 https://www.redeye.se/research/1148675/eg7-q4-preview-continued-fx-headwind https://www.redeye.se/research/1148675/eg7-q4-preview-continued-fx-headwind"
X Link 2026-02-11T08:59Z 14.4K followers, [---] engagements
"Redeye comments on Hansa Biopharma's Q4 report. $HNSA https://www.redeye.se/research/1148656/hansa-biopharma-q4-initial-take-strong-european-sales-beats-forecast https://www.redeye.se/research/1148656/hansa-biopharma-q4-initial-take-strong-european-sales-beats-forecast"
X Link 2026-02-11T09:44Z 14.4K followers, [---] engagements
"Redeye comments briefly on Insplorions announcement following the Boards strategic review. $INSP https://www.redeye.se/research/1148847/insplorion-divesting-its-core-business https://www.redeye.se/research/1148847/insplorion-divesting-its-core-business"
X Link 2026-02-11T14:54Z 14.4K followers, [---] engagements
"Redeye comments on Devyser reaching a 25% EBIT margin and record sales with strong operating cash flow. We expect the share to trade upwards 15% today. $DVYSR https://www.redeye.se/research/1149167/devyser-q4-initial-take-a-strong-end-to-2025 https://www.redeye.se/research/1149167/devyser-q4-initial-take-a-strong-end-to-2025"
X Link 2026-02-12T09:13Z 14.4K followers, [---] engagements
"Redeye provides its first take on Camurus Q4 report [----] published this morning. $CAMX https://www.redeye.se/research/1149158/camurus-q4-initial-take-europe-continued-decline-us-growth https://www.redeye.se/research/1149158/camurus-q4-initial-take-europe-continued-decline-us-growth"
X Link 2026-02-12T09:46Z 14.4K followers, [---] engagements
"Redeye comments on Tradedoubler's Q4 report being impacted by a significant revaluation of the KaHa earnout liability which masked a relatively stable underlying performance. $TRAD https://www.redeye.se/research/1143265/tradedoubler-q4-initial-take-underlying-performance-largely-in-line https://www.redeye.se/research/1143265/tradedoubler-q4-initial-take-underlying-performance-largely-in-line"
X Link 2026-02-12T09:47Z 14.4K followers, [---] engagements
"Redeye provides its initial take on Ferroamps Q4 numbers which presented strong sales growth and significantly improved profitability y-o-y. $FERRO https://www.redeye.se/research/1149240/ferroamp-q4-initial-take-very-strong-sales-development https://www.redeye.se/research/1149240/ferroamp-q4-initial-take-very-strong-sales-development"
X Link 2026-02-12T09:48Z 14.4K followers, [---] engagements
"Redeye provides its initial take on Acarixs Q4 report which beat our topline estimates while costs were somewhat higher than we had anticipated. $ACARIX https://www.redeye.se/research/1149270/acarix-q4-inital-take-beat-on-topline https://www.redeye.se/research/1149270/acarix-q4-inital-take-beat-on-topline"
X Link 2026-02-12T09:49Z 14.4K followers, [---] engagements
"Redeye comments on Litiums Q4 which showed solid momentum with 18% ARR growth and net sales above our expectations. $LITI https://www.redeye.se/research/1148277/litium-q4-initial-take-record-order-intake https://www.redeye.se/research/1148277/litium-q4-initial-take-record-order-intake"
X Link 2026-02-12T09:50Z 14.4K followers, [---] engagements
"Redeye's immediate impression of Stille's year-end report [----] is positive. $STIL https://www.redeye.se/research/1146011/stille-q4-initial-take-beat-across-the-board-despite-fx-headwinds https://www.redeye.se/research/1146011/stille-q4-initial-take-beat-across-the-board-despite-fx-headwinds"
X Link 2026-02-12T09:51Z 14.4K followers, [---] engagements
"Redeye notes that as anticipated Genovis year-end report showcased robust top-line momentum with sharp sales growth following the SEK 11m ADC-order announced in Q4. $GENO https://www.redeye.se/research/1146004/genovis-q4-initial-take-in-line-with-our-estimates https://www.redeye.se/research/1146004/genovis-q4-initial-take-in-line-with-our-estimates"
X Link 2026-02-12T09:56Z 14.4K followers, [---] engagements
"Redeye considers Polygienes Q4'25 figures to be soft missing our expectations by 18% on top-line primarily driven by lower Polygiene sales. $POLYG https://www.redeye.se/research/1148755/polygiene-group-q4-initial-take-softer-than-expected https://www.redeye.se/research/1148755/polygiene-group-q4-initial-take-softer-than-expected"
X Link 2026-02-12T09:57Z 14.4K followers, [---] engagements
"Redeye comments on Hansa Biopharma's Q4 report. $HNSA https://www.redeye.se/research/1148786/hansa-biopharma-q4-update-strong-quarter-in-europe https://www.redeye.se/research/1148786/hansa-biopharma-q4-update-strong-quarter-in-europe"
X Link 2026-02-12T10:45Z 14.4K followers, [---] engagements
"Redeye notes that AVTECH's Q4 [----] results aligned with preliminary figures whilst falling short of the firm's estimates by 11% on sales and 10% on adjusted EBITDA. $AVT https://www.redeye.se/research/1147769/avtech-q4-initial-take-pre-announced-results-set-stage-for-modest-base-case-recalibration https://www.redeye.se/research/1147769/avtech-q4-initial-take-pre-announced-results-set-stage-for-modest-base-case-recalibration"
X Link 2026-02-06T08:29Z 14.4K followers, [---] engagements
"Redeye revises its base case to SEK10(SEK12) following AVTECH's Q4 [----] results which fell 11% short on net sales owing to anticipated contracts failing to materialise. $AVT https://www.redeye.se/research/1148102/avtech-q4-review-40-de-rating-leads-to-increasingly-compelling-setup https://www.redeye.se/research/1148102/avtech-q4-review-40-de-rating-leads-to-increasingly-compelling-setup"
X Link 2026-02-09T08:58Z 14.4K followers, [---] engagements
"Redeye has interviewed AVTECHs CEO David Rytter to discuss the past year future development and the current sales pipeline. $AVT https://www.redeye.se/research/1147928/avtech-q4-interview-redeye-speaks-with-ceo-david-ritter https://www.redeye.se/research/1147928/avtech-q4-interview-redeye-speaks-with-ceo-david-ritter"
X Link 2026-02-09T09:02Z 14.4K followers, [---] engagements
"Redeye comments on SynAct Pharma's full recruitment of the phase IIb ADVANCE study in RA with [---] patients. $SYNACT https://www.redeye.se/research/1148168/synact-pharma-last-patient-included https://www.redeye.se/research/1148168/synact-pharma-last-patient-included"
X Link 2026-02-09T09:04Z 14.4K followers, [---] engagements
"Redeye retains its positive view of CombinedX following the Q4 report. $CX https://www.redeye.se/research/1148430/combinedx-q4-initial-take-solid-underlying-profitability-slightly-revised-strategy https://www.redeye.se/research/1148430/combinedx-q4-initial-take-solid-underlying-profitability-slightly-revised-strategy"
X Link 2026-02-11T09:45Z 14.4K followers, [---] engagements
"Redeye comments on todays press release from Waystream announcing that Telia Estonia has placed a SEK9m follow-up order for access switches. $WAYS https://www.redeye.se/research/1149044/waystream-telia-estonia-scales-up-with-sek9m-order https://www.redeye.se/research/1149044/waystream-telia-estonia-scales-up-with-sek9m-order"
X Link 2026-02-11T15:21Z 14.4K followers, [---] engagements
"Redeye comments on Vertiseits Q4 report showing somewhat lower organic ARR growth and higher OPEX than expected. $VERT https://www.redeye.se/research/1148503/vertiseit-q4-initial-take-somewhat-soft-q4-positive-outlook https://www.redeye.se/research/1148503/vertiseit-q4-initial-take-somewhat-soft-q4-positive-outlook"
X Link 2026-02-12T09:10Z 14.4K followers, [---] engagements
"Redeye comments on Carasents Q4 report showing slightly lower organic ARR growth yet solid scalability. $CARA https://www.redeye.se/research/1148492/carasent-q4-initial-take-reaching-2025-targets https://www.redeye.se/research/1148492/carasent-q4-initial-take-reaching-2025-targets"
X Link 2026-02-12T09:11Z 14.4K followers, [---] engagements
"Redeye comments on RaySearch delivering a strong Q4 with record sales above consensus estimates and record EBIT also above consensus estimates. $RAY https://www.redeye.se/research/1149210/raysearch-laboratories-q4-initial-take-another-record-quarter https://www.redeye.se/research/1149210/raysearch-laboratories-q4-initial-take-another-record-quarter"
X Link 2026-02-12T09:44Z 14.4K followers, [---] engagements
"Redeye is encouraged by Nekkars financial recovery during the fourth quarter which posted a 30% beat on top-line and a [--] p.p stronger EBITDA margin compared to our relatively low set expectations. $NKR https://www.redeye.se/research/1148908/nekkar-q4-initial-take-better-than-expected https://www.redeye.se/research/1148908/nekkar-q4-initial-take-better-than-expected"
X Link 2026-02-12T09:48Z 14.4K followers, [---] engagements
"Redeye comments on Limes Q4 report showing 10% organic ARR growth slightly below our expectations. $LIME https://www.redeye.se/research/1148514/lime-q4-initial-take-slightly-below-expectations https://www.redeye.se/research/1148514/lime-q4-initial-take-slightly-below-expectations"
X Link 2026-02-12T09:51Z 14.4K followers, [---] engagements
"Redeye har intervjuat Active Biotechs vd Heln Tuvesson om Q4 rapporten med ett fokus p nyemissionen tasquinimod och laquinimod. $ACTI https://www.redeye.se/research/1149396/active-biotech-q4-intervju-redeye-pratar-med-vd-helen-tuvesson https://www.redeye.se/research/1149396/active-biotech-q4-intervju-redeye-pratar-med-vd-helen-tuvesson"
X Link 2026-02-12T13:47Z 14.4K followers, [---] engagements
"Redeye retains its positive view of CombinedX following a solid Q4 with strong underlying margins. $CX https://www.redeye.se/research/1148424/combinedx-q4-review-entering-2026-with-renewed-vision https://www.redeye.se/research/1148424/combinedx-q4-review-entering-2026-with-renewed-vision"
X Link 2026-02-13T08:59Z 14.4K followers, [---] engagements
"Redeye retains its positive view of Lime following the Q4 report. $LIME https://www.redeye.se/research/1148509/lime-q4-review-solid-fundamentals-despite-ai-squeeze https://www.redeye.se/research/1148509/lime-q4-review-solid-fundamentals-despite-ai-squeeze"
X Link 2026-02-13T09:00Z 14.4K followers, [---] engagements
"Redeye provides an update following Neola Medicals Q4 [----] report. $NEOLA https://www.redeye.se/research/1149522/neola-medical-q4-review-eyes-on-upcoming-clinical-data https://www.redeye.se/research/1149522/neola-medical-q4-review-eyes-on-upcoming-clinical-data"
X Link 2026-02-13T09:01Z 14.4K followers, [---] engagements
"Redeye updates on W5 Solutions following Q4 results that exceeded expectations. $W5 https://www.redeye.se/research/1149923/w5-solutions-q4-review-strong-year-end-and-positive-outlook https://www.redeye.se/research/1149923/w5-solutions-q4-review-strong-year-end-and-positive-outlook"
X Link 2026-02-13T09:02Z 14.4K followers, [---] engagements
"Redeye comments on Lytix' third quarter report [----]. $LYTIX https://www.redeye.se/research/1149495/lytix-biopharma-q4-review-well-funded-to-deliver-in-26 https://www.redeye.se/research/1149495/lytix-biopharma-q4-review-well-funded-to-deliver-in-26"
X Link 2026-02-13T09:02Z 14.4K followers, [---] engagements
"Redeye has interviewed Litium's CEO Martin Billenius who shares insights on the Q4 report the plans for [----] and the partnership with Monitor ERP. $LITI https://www.redeye.se/research/1149616/litium-q4-interview-redeye-speaks-with-ceo-martin-billenius https://www.redeye.se/research/1149616/litium-q4-interview-redeye-speaks-with-ceo-martin-billenius"
X Link 2026-02-13T09:04Z 14.4K followers, [---] engagements
"Redeye comments on Stilles soft share price developing over the past months to us appears more sentiment-driven than fundamental following the Q4 report. $STIL https://www.redeye.se/research/1148540/__trashed-2 https://www.redeye.se/research/1148540/__trashed-2"
X Link 2026-02-13T09:08Z 14.4K followers, [---] engagements
"Redeye views BeammWave's Q4 [----] report as a positive read with the share price likely to respond favourably to management's visible confidence better-than-expected cost discipline and continued momentum across all three customer verticals. $BEAMMW https://www.redeye.se/research/1149960/beammwave-q4-initial-take-execution-now-the-only-variable https://www.redeye.se/research/1149960/beammwave-q4-initial-take-execution-now-the-only-variable"
X Link 2026-02-13T09:08Z 14.4K followers, [---] engagements
"Redeye provides an update following Acarixs Q4 [----] report. $ACARIX https://www.redeye.se/research/1150002/acarix-q4-review-a-solid-end-to-2025 https://www.redeye.se/research/1150002/acarix-q4-review-a-solid-end-to-2025"
X Link 2026-02-13T09:09Z 14.4K followers, [---] engagements
"Redeye provides its initial take on Relais Q4 [----] report which featured an adjusted EBITA that aligned with our projection but a slightly soft organic growth amid a challenging market situation. $RELAIS https://www.redeye.se/research/1150093/relais-q4-initial-take-solid-profitability-softer-organic-growth https://www.redeye.se/research/1150093/relais-q4-initial-take-solid-profitability-softer-organic-growth"
X Link 2026-02-13T09:10Z 14.4K followers, [---] engagements
"Redeye sees Safetures Q4 [----] report to be another step in the right direction with positive ARR growth improving gross margin and solid cost control resulting in a positive EBIT. $SFTR https://www.redeye.se/research/1148745/safeture-q4-initial-take-sequential-improvements https://www.redeye.se/research/1148745/safeture-q4-initial-take-sequential-improvements"
X Link 2026-02-13T09:11Z 14.4K followers, [---] engagements
"Redeye has interviewed Invisios CEO Lars Hjgrd Hansen in connection with the company's Q4-results. $IVSO https://www.redeye.se/research/1150121/invisio-q4-interview-redeye-speaks-with-ceo-lars-hojgard-hansen https://www.redeye.se/research/1150121/invisio-q4-interview-redeye-speaks-with-ceo-lars-hojgard-hansen"
X Link 2026-02-13T09:39Z 14.4K followers, [---] engagements
"NanoEcho utvecklar framtidens rektalcancerdiagnostik. Idag startar teckningsperioden i bolagets fretrdesemission p upp till [----] MSEK fr att ta nsta steg med sin PoC-studie. Ls mer om transaktionen: Se VD Linda Perssons hisspitch: https://www.redeye.se/video/transaction/1149074/nanoecho-hisspitchutm_source=twitter&utm_medium=social&utm_campaign=nefeq126&utm_content=image https://www.redeye.se/transaction/nanoecho-ab-(publ)-utm_source=twitter&utm_medium=social&utm_campaign=nefeq126&utm_content=image"
X Link 2026-02-13T10:01Z 14.4K followers, [---] engagements
"Redeye updates on Better Collective ahead of Q4-results (due [--] February after market close) where we expect a solid year-end performance supported by positive seasonality. $BETCO https://www.redeye.se/research/1149964/better-collective-q4-preview-solid-year-end-expected https://www.redeye.se/research/1149964/better-collective-q4-preview-solid-year-end-expected"
X Link 2026-02-13T09:04Z 14.4K followers, [---] engagements
"Redeye has interviewed Acarix's CEO Aamir Mahmood following the release of the companys Q4 [----] report. $ACARIX https://www.redeye.se/research/1149628/acarix-q4-interview-redeye-speaks-with-ceo-aamir-mahmood https://www.redeye.se/research/1149628/acarix-q4-interview-redeye-speaks-with-ceo-aamir-mahmood"
X Link 2026-02-13T11:01Z 14.4K followers, [---] engagements
"Redeye keeps its positive view of Vertiseit following a decent Q4 report. $VERT https://www.redeye.se/research/1148498/vertiseit-q4-review-long-term-story-intact-ai-resilience-from-the-back-end https://www.redeye.se/research/1148498/vertiseit-q4-review-long-term-story-intact-ai-resilience-from-the-back-end"
X Link 2026-02-13T08:58Z 14.4K followers, [---] engagements
"Redeye returns with an update on Sprint Bioscience following recent events and the Q4 report. $SPRINT https://www.redeye.se/research/1148578/sprint-bioscience-q4-review-promising-development https://www.redeye.se/research/1148578/sprint-bioscience-q4-review-promising-development"
X Link 2026-02-13T09:58Z 14.4K followers, [---] engagements
"Redeye concludes that Litium delivered a strong Q4 with ARR growth of 18% including Geins and organic growth of 9%. $LITI https://www.redeye.se/research/1148574/litium-q4-review-adding-growth-to-the-basket-in-h2 https://www.redeye.se/research/1148574/litium-q4-review-adding-growth-to-the-basket-in-h2"
X Link 2026-02-13T14:47Z 14.4K followers, [---] engagements
"Redeye publishes a preview of Transtemas Q2 report. $TRANS https://www.redeye.se/research/1117172/transtema-q2-preview-breakthrough-deal-in-power-and-lowered-short-term-margin-assumptions https://www.redeye.se/research/1117172/transtema-q2-preview-breakthrough-deal-in-power-and-lowered-short-term-margin-assumptions"
X Link 2025-07-10T06:58Z 14.5K followers, [---] engagements
"Redeye is growing more optimistic about the investment case in Oncopeptides after two news items this week: the inclusion of Pepaxti in the EHA-EMN guidelines and strong sales growth in Q2. $ONCO https://www.redeye.se/research/1117317/oncopeptides-positive-momentum https://www.redeye.se/research/1117317/oncopeptides-positive-momentum"
X Link 2025-07-10T09:01Z 14.5K followers, [----] engagements
"Redeye har intervjuat Nanologicas vd Andreas Bhagwani. Vi diskuterar bland annat Q2-rapporten framsteg i produktionen nya kunder i USA&Kina och kassapositionen. $NICA https://www.redeye.se/research/1117374/nanologica-q225-intervju-med-vd-andreas-bhagwani https://www.redeye.se/research/1117374/nanologica-q225-intervju-med-vd-andreas-bhagwani"
X Link 2025-07-10T15:49Z 14.5K followers, [---] engagements
"Redeye updates its production estimates ahead of Arise's Q2 report on Friday next week (18 July). $ARISE https://www.redeye.se/research/1117621/arise-updated-estimates-ahead-of-the-q2-report https://www.redeye.se/research/1117621/arise-updated-estimates-ahead-of-the-q2-report"
X Link 2025-07-11T06:14Z 14.5K followers, [---] engagements
"Redeye updates its view on Nanologica following the Q2 report. $NICA https://www.redeye.se/research/1116790/nanologica-q2-2025-low-near-term-visibility-but-encouraging-long-term-case https://www.redeye.se/research/1116790/nanologica-q2-2025-low-near-term-visibility-but-encouraging-long-term-case"
X Link 2025-07-11T06:14Z 14.5K followers, [----] engagements
"Redeye comments on Limes Q2 report showing solid underlying numbers despite sales being hurt by soft Expert services. $LIME https://www.redeye.se/research/1117639/lime-q2-2025-solid-key-figures-softer-consulting-hurting-sales https://www.redeye.se/research/1117639/lime-q2-2025-solid-key-figures-softer-consulting-hurting-sales"
X Link 2025-07-11T08:26Z 14.5K followers, [---] engagements
"Redeye comments on XVIVO's major US setback with a period of elevated uncertainty in the US lung market. $XVIVO https://www.redeye.se/research/1117702/xvivo-a-major-us-setback-with-a-period-of-elevated-uncertainty-in-the-us-lung-market https://www.redeye.se/research/1117702/xvivo-a-major-us-setback-with-a-period-of-elevated-uncertainty-in-the-us-lung-market"
X Link 2025-07-11T09:38Z 14.5K followers, [----] engagements
"Redeye updates its Base Case and forecasts for Lime following the Q2 report. $LIME https://www.redeye.se/research/1117708/lime-breakthrough-among-german-utilities https://www.redeye.se/research/1117708/lime-breakthrough-among-german-utilities"
X Link 2025-07-14T06:06Z 14.5K followers, [---] engagements
"Redeye provides an update following Iconovos Q2 report. $ICO https://www.redeye.se/research/1117906/iconovo-q2-an-undramatic-report-with-early-signs-of-cost-reductions https://www.redeye.se/research/1117906/iconovo-q2-an-undramatic-report-with-early-signs-of-cost-reductions"
X Link 2025-07-15T06:06Z 14.5K followers, [---] engagements
"Redeye comments on XVIVOs Q2 revealing an unexpectedly sharp slowdown in its US lung business. The magnitude of the decline coupled with limited near-term visibility came as a surprise not only to investors but also to key customers. $XVIVO https://www.redeye.se/api/articles/download-file/17b1f93f-82ee-34ed-aca2-eaf1356cdf2d/XVIVO%3A%20A%20major%20challenge%20triggers%20a%20major%20opportunity https://www.redeye.se/api/articles/download-file/17b1f93f-82ee-34ed-aca2-eaf1356cdf2d/XVIVO%3A%20A%20major%20challenge%20triggers%20a%20major%20opportunity"
X Link 2025-07-15T07:41Z 14.5K followers, [----] engagements
"Redeye comments on this morning's press release from Arise stating that it has reached an agreement with Foresight regarding the earn-out payment for Klvallen of approx. EUR30m. $ARISE https://www.redeye.se/research/1118403/arise-eur30m-earn-out-payment-secured https://www.redeye.se/research/1118403/arise-eur30m-earn-out-payment-secured"
X Link 2025-07-16T08:10Z 14.5K followers, [----] engagements
"Redeye comments on Evolutions Q2-results which were in line with our expectations albeit with slightly softer topline but somewhat stronger profitability. $EVO https://www.redeye.se/research/1118672/evolution-q2-2025-results-as-expected-guidance-reiterated https://www.redeye.se/research/1118672/evolution-q2-2025-results-as-expected-guidance-reiterated"
X Link 2025-07-17T07:17Z 14.5K followers, [----] engagements
"Redeye comments on OncoZenges recent amendment to its licensing agreement with Molteni Farmaceutici which accelerates EUR550000 in milestone payments to coincide with CTA approval. $ONCOZ https://www.redeye.se/research/1118804/oncozenge-shifts-to-a-fully-european-phase-iii-study https://www.redeye.se/research/1118804/oncozenge-shifts-to-a-fully-european-phase-iii-study"
X Link 2025-07-17T08:17Z 14.5K followers, [---] engagements
"Redeye comments on CombinedXs Q2 report showing negative growth and lower margins than expected. On the positive note the underlying data looks relatively solid. $CX https://www.redeye.se/research/1118515/combinedx-q2-2025-lower-sales-hurting https://www.redeye.se/research/1118515/combinedx-q2-2025-lower-sales-hurting"
X Link 2025-07-17T12:32Z 14.5K followers, [---] engagements
"Redeye updates on Evolution post Q2-results which were largely in line with our forecasts. $EVO https://www.redeye.se/research/1119241/evolution-asia-back-to-growth https://www.redeye.se/research/1119241/evolution-asia-back-to-growth"
X Link 2025-07-18T07:16Z 14.5K followers, [----] engagements
"Redeye provides its first take on Cellavisions Q2 report [----] published this morning. $CEVI https://www.redeye.se/research/1119287/cellavision-q2-2025-first-review-of-the-results https://www.redeye.se/research/1119287/cellavision-q2-2025-first-review-of-the-results"
X Link 2025-07-18T07:16Z 14.5K followers, [---] engagements
"Redeye comments on Annexins Q2 report and recent events in the company. $ANNX https://www.redeye.se/research/1119256/annexin-q2-positioned-to-advance-dr-study-and-bd-efforts https://www.redeye.se/research/1119256/annexin-q2-positioned-to-advance-dr-study-and-bd-efforts"
X Link 2025-07-18T07:18Z 14.5K followers, [---] engagements
"Redeye comments on the takeover offer on Bredband2 from Telia Company. $BRE2 https://www.redeye.se/research/1119356/bredband2-takeover-offer-from-telia https://www.redeye.se/research/1119356/bredband2-takeover-offer-from-telia"
X Link 2025-07-18T07:19Z 14.5K followers, [----] engagements
"Redeye updates on InfraCom following Telias bid for Bredband2 at SEK3.25 per share InfraCom has agreed to tender its shares. $INFRA https://www.redeye.se/research/1119411/infracom-cashing-in-on-telias-bid-for-bredband2 https://www.redeye.se/research/1119411/infracom-cashing-in-on-telias-bid-for-bredband2"
X Link 2025-07-18T07:21Z 14.5K followers, [----] engagements
"Redeye comments on Arises Q2 report which saw higher production than expected driving the segment's earnings generation. $ARISE https://www.redeye.se/research/1119441/arise-q2-2025-underlying-solid https://www.redeye.se/research/1119441/arise-q2-2025-underlying-solid"
X Link 2025-07-18T09:59Z 14.5K followers, [---] engagements
"Redeye updates its estimates and fair value range following Arises Q2 report. $ARISE https://www.redeye.se/research/1120283/arise-enters-the-harvesting-period https://www.redeye.se/research/1120283/arise-enters-the-harvesting-period"
X Link 2025-07-21T05:53Z 14.5K followers, [---] engagements
"Redeye comments on Cellavision's first quarter [----] which saw organic sales growth of 8% with the highest growth in ASEA. $CEVI https://www.redeye.se/research/1119494/cellavision-q2-2025-stable-with-decent-growth https://www.redeye.se/research/1119494/cellavision-q2-2025-stable-with-decent-growth"
X Link 2025-07-21T06:01Z 14.5K followers, [----] engagements
"Redeye provides its initial take on MedCaps Q2 [----] report which roughly matched our top-line projection and beat our adjusted EBITA estimate. $MCAP https://www.redeye.se/research/1120410/medcap-q2-2025-ebita-beat-thesis-playing-out-as-expected https://www.redeye.se/research/1120410/medcap-q2-2025-ebita-beat-thesis-playing-out-as-expected"
X Link 2025-07-23T06:10Z 14.5K followers, [----] engagements
"Redeye returns with a more in-depth take on Devyser's Q2 report. $DVYSR https://www.redeye.se/research/1120405/devyser-q2-profitable-from-here-on https://www.redeye.se/research/1120405/devyser-q2-profitable-from-here-on"
X Link 2025-07-23T06:12Z 14.5K followers, [----] engagements
"Redeye updates its estimates and valuation following MedCaps Q2 [----] report. $MCAP https://www.redeye.se/research/1120433/medcap-q2-2025-the-rise-fall-and-rise-again https://www.redeye.se/research/1120433/medcap-q2-2025-the-rise-fall-and-rise-again"
X Link 2025-07-23T12:00Z 14.5K followers, [----] engagements
"Redeye comments on Safello announcing a partnership with Marginalen Bank positioning itself as the first crypto broker to offer a comprehensive suite of banking services to its customers. $SFL https://www.redeye.se/research/1120731/safello-a-strategic-leap-into-traditional-finance https://www.redeye.se/research/1120731/safello-a-strategic-leap-into-traditional-finance"
X Link 2025-07-25T06:14Z 14.5K followers, [----] engagements
"Redeye provides a comment on DalaVinds divestment of Fagersen an onshore wind project of more than 200MW to OX2. $DE https://www.redeye.se/research/1120847/dala-energi-dalavind-divests-fagerasen https://www.redeye.se/research/1120847/dala-energi-dalavind-divests-fagerasen"
X Link 2025-07-25T14:21Z 14.5K followers, [---] engagements
"Redeye comments on XVIVO's delayed launch being a setback for both XVIVO patients and specialist centers waiting to use the solution. $XVIVO https://www.redeye.se/research/1121170/xvivo-the-european-heart-launch-is-delayed-for-6-12-months https://www.redeye.se/research/1121170/xvivo-the-european-heart-launch-is-delayed-for-6-12-months"
X Link 2025-07-29T11:59Z 14.5K followers, [----] engagements
"Redeye comments on the partnership with SD Pharma in Spain which will broaden physician reach of Pepaxti. $ONCO https://www.redeye.se/research/1121191/oncopeptides-partnership-can-help-accelerate-spanish-sales https://www.redeye.se/research/1121191/oncopeptides-partnership-can-help-accelerate-spanish-sales"
X Link 2025-07-30T08:17Z 14.5K followers, [----] engagements
"Redeye gives an initial comment on the Leqembi royalty for Q2 and the presentations from AAIC. $BIOA https://www.redeye.se/research/1121261/bioarctic-solid-q2-royalty-and-further-supporting-data-from-aaic https://www.redeye.se/research/1121261/bioarctic-solid-q2-royalty-and-further-supporting-data-from-aaic"
X Link 2025-08-01T12:23Z 14.5K followers, [---] engagements
"Redeye leaves its preview of RaySearchs Q2 [----] results due on Friday August [--]. $RAY https://www.redeye.se/research/1121317/raysearch-redeye-q2-2025e-preview https://www.redeye.se/research/1121317/raysearch-redeye-q2-2025e-preview"
X Link 2025-08-04T10:48Z 14.5K followers, [----] engagements
"Redeye comments briefly on Insplorions recent update on strategic development and ongoing key initiatives. $INSP https://www.redeye.se/research/1121396/insplorion-business-activity-update https://www.redeye.se/research/1121396/insplorion-business-activity-update"
X Link 2025-08-06T06:23Z 14.5K followers, [----] engagements
"Redeye comments on Avtech announcing a three-year extension to its agreement with Wizz Air significantly expanding the scope of the original contract signed in late [----]. $AVT https://www.redeye.se/research/1121444/avtech-bags-an-upsell-with-wizz-air-expansion https://www.redeye.se/research/1121444/avtech-bags-an-upsell-with-wizz-air-expansion"
X Link 2025-08-06T15:33Z 14.5K followers, [----] engagements
"Redeye updates on Embracer ahead of Q1-results (due [--] August) where we forecast a slow start to 2025/26E with new few game releases while we expect guidance for the full year to be reiterated. $EMBRAC https://www.redeye.se/research/1121449/embracer-preview-q1-2025-26e-slow-start-to-the-year-expected https://www.redeye.se/research/1121449/embracer-preview-q1-2025-26e-slow-start-to-the-year-expected"
X Link 2025-08-07T06:47Z 14.5K followers, [----] engagements
"Redeye comments on G5s Q2-results where results were weaker than expected partly driven by USD/SEK while gross margin remained strong owing to continued growth of the G5 Store. $G5EN https://www.redeye.se/research/1121476/g5-entertaiment-q2-2025-continued-soft-topline-development https://www.redeye.se/research/1121476/g5-entertaiment-q2-2025-continued-soft-topline-development"
X Link 2025-08-07T06:49Z 14.5K followers, [----] engagements
"Redeye provides an update following Optomeds Q2 [----] report. $OPTOMED https://www.redeye.se/research/1121556/optomed-q2-soft-q2-sales-raises-the-stakes-for-h2-recovery https://www.redeye.se/research/1121556/optomed-q2-soft-q2-sales-raises-the-stakes-for-h2-recovery"
X Link 2025-08-08T06:54Z 14.5K followers, [---] engagements
"Redeye returns with a more in-depth take on Raysearchs Q2 report. $RAY https://www.redeye.se/research/1121657/raysearch-q2-gearing-up-for-more-record-quarters https://www.redeye.se/research/1121657/raysearch-q2-gearing-up-for-more-record-quarters"
X Link 2025-08-11T06:36Z 14.5K followers, [----] engagements
"Redeye comments on Q2 confirming that Mobergs Terclara is now the market leader in both Sweden and Norway. $MOB https://www.redeye.se/research/1121805/moberg-pharma-q2-teclara-is-the-clear-market-leader-in-both-sweden-and-norway https://www.redeye.se/research/1121805/moberg-pharma-q2-teclara-is-the-clear-market-leader-in-both-sweden-and-norway"
X Link 2025-08-12T07:20Z 14.5K followers, [----] engagements
"Moberg Pharma is trading below Redeye's Base Case. We spoke with our analyst about Moberg Pharma's choice between direct sales and partner-led distribution the role of internal R&D and more. This is a premium article included in our paid plans from SEK 99/month. $MOB https://www.redeye.se/research/1121700/moberg-pharma-expanding-its-european-otc-footprint https://www.redeye.se/research/1121700/moberg-pharma-expanding-its-european-otc-footprint"
X Link 2025-08-12T08:50Z 14.5K followers, [----] engagements
"Redeye provides an update after Q2 confirms that Mobergs Terclara is now the market leader in both Sweden and Norway. Consumer marketing activities and a strong channel presence have resulted in high market shares of 44% in Sweden (value) and 43% in Norway (value). $MOB https://www.redeye.se/research/1122178/moberg-pharma-terclara-is-the-market-leader-in-both-sweden-and-norway https://www.redeye.se/research/1122178/moberg-pharma-terclara-is-the-market-leader-in-both-sweden-and-norway"
X Link 2025-08-13T07:24Z 14.5K followers, [----] engagements
"Redeye comments on Embracers Q1-results which were weaker than expected owing mainly to soft performance in PC/Console. $EMBRAC https://www.redeye.se/research/1122352/embracer-q1-2025-26-soft-q1-and-lowered-guidance https://www.redeye.se/research/1122352/embracer-q1-2025-26-soft-q1-and-lowered-guidance"
X Link 2025-08-14T06:27Z 14.5K followers, [----] engagements
"Redeye comments on Bredband2s Q2 report which posted marginally stronger performance across the board with stronger sales and lower OPEX. $BRE2 https://www.redeye.se/research/1122373/bredband2-q2-2025-solid-figures-telia-takeover-in-spotlight https://www.redeye.se/research/1122373/bredband2-q2-2025-solid-figures-telia-takeover-in-spotlight"
X Link 2025-08-14T14:08Z 14.5K followers, [---] engagements
"Top Picks makes an update following a minor change in the portfolio where we are increasing our stake in a bet that has been punished way too much by the market. Top Picks is included in our premium memberships from SEK 349/month. $XVIVO https://www.redeye.se/research/1122369/top-picks-when-the-market-gives-you-lemons-make-lemonade https://www.redeye.se/research/1122369/top-picks-when-the-market-gives-you-lemons-make-lemonade"
X Link 2025-08-14T14:09Z 14.5K followers, [----] engagements
"Redeye states Safellos Q2 [----] presented top-line headwinds with net sales of SEK130.8m falling 20% short of Redeye Research Estimates. $SFL https://www.redeye.se/research/1122474/safello-q2-2025-continued-headwinds https://www.redeye.se/research/1122474/safello-q2-2025-continued-headwinds"
X Link 2025-08-15T07:13Z 14.5K followers, [----] engagements
"Redeye notes Safellos headwinds from Q1 continued into Q2 [----] with net sales disappointing resulting in an adjusted EBITDA loss of SEK4.9m. $SFL https://www.redeye.se/research/1122538/safello-navigating-a-critical-crossroads https://www.redeye.se/research/1122538/safello-navigating-a-critical-crossroads"
X Link 2025-08-18T06:43Z 14.5K followers, [----] engagements
"Redeye comments on Ascelia progressing with the Orviglance application and the company is about to complete the electronic configuration of the file. $ACE https://www.redeye.se/research/1122629/ascelia-pharma-good-us-orviglance-news https://www.redeye.se/research/1122629/ascelia-pharma-good-us-orviglance-news"
X Link 2025-08-18T06:54Z 14.5K followers, [----] engagements
"Redeye comments on Nitro Games' Q2 [----] report which came in softer than expected both in terms of top line and profitability. $NITRO https://www.redeye.se/research/1121735/nitro-games-q2-2025-softer-than-expected https://www.redeye.se/research/1121735/nitro-games-q2-2025-softer-than-expected"
X Link 2025-08-18T06:55Z 14.5K followers, [----] engagements
"Redeye provides an update following Nitro Games Q2 [----] report which was softer than expected. $NITRO https://www.redeye.se/research/1121743/nitro-games-rising-uncertainty https://www.redeye.se/research/1121743/nitro-games-rising-uncertainty"
X Link 2025-08-19T06:32Z 14.5K followers, [---] engagements
"Redeye comments on Gentoo Media ahead of Q2-results (due [--] August) were focus is on margin recovery after unusually soft profitability in Q1 on the back of the regulation in Brazil. $G2MNO https://www.redeye.se/research/1122924/gentoo-media-preview-q2-2025e-margin-recovery-in-focus https://www.redeye.se/research/1122924/gentoo-media-preview-q2-2025e-margin-recovery-in-focus"
X Link 2025-08-19T06:32Z 14.5K followers, [---] engagements
"Redeye give its comments on Starbreeze's Q2 report; After a strong Q1 report where Payday [--] was included for all PlayStation subscribers creating strong momentum in terms of player engagement our expectations were raised a bit too high. $STAR https://www.redeye.se/research/1122324/starbreeze-q2-2025-weaker-playstation-plus-boost-than-expected https://www.redeye.se/research/1122324/starbreeze-q2-2025-weaker-playstation-plus-boost-than-expected"
X Link 2025-08-19T09:00Z 14.5K followers, [---] engagements
"Redeye provides an initial take on the Q2 [----] report from Cheffelo which came in slightly below our estimates but in line with what could be expected following the trading update. $CHEF https://www.redeye.se/research/1123058/cheffelo-q2-2025-no-drama https://www.redeye.se/research/1123058/cheffelo-q2-2025-no-drama"
X Link 2025-08-20T07:26Z 14.5K followers, [----] engagements
"Redeye updates its estimates and valuation following the Q2 [----] report from Cheffelo. $CHEF https://www.redeye.se/research/1123102/cheffelo-momentum-remains-on-the-menu https://www.redeye.se/research/1123102/cheffelo-momentum-remains-on-the-menu"
X Link 2025-08-21T06:13Z 14.5K followers, [----] engagements
"Redeye provides its initial take on Surgical Sciences Q2 [----] report which aligned with its profit warning and underperformed our original projections across the board. $SUS https://www.redeye.se/research/1123724/surgical-science-q2-2025-in-line-with-profit-warning https://www.redeye.se/research/1123724/surgical-science-q2-2025-in-line-with-profit-warning"
X Link 2025-08-21T06:15Z 14.5K followers, [----] engagements
"Redeye comments on Ascelias two most important value drivers being the US submission which is now de-risked and Ascelia is expecting a submission in early September. $ACE https://www.redeye.se/research/1123807/ascelia-pharma-just-about-to-submit-orviglance-for-us-approval https://www.redeye.se/research/1123807/ascelia-pharma-just-about-to-submit-orviglance-for-us-approval"
X Link 2025-08-21T07:56Z 14.5K followers, [----] engagements
"Redeye comments on Starbreeze's weaker-than-expected quarter regarding revenue and profitability; however we are raising our sales estimates for the second half of [----]. $STAR https://www.redeye.se/research/1122420/starbreeze-effect-from-publishing-switch-in-q3 https://www.redeye.se/research/1122420/starbreeze-effect-from-publishing-switch-in-q3"
X Link 2025-08-21T08:00Z 14.5K followers, [---] engagements
"Redeye updates its estimates following Surgical Sciences Q2 [----] report which aligned with the companys profit warning and broadly underperformed our original projections. $SUS https://www.redeye.se/research/1124019/surgical-science-q2-2025-expect-continued-volatility https://www.redeye.se/research/1124019/surgical-science-q2-2025-expect-continued-volatility"
X Link 2025-08-22T07:01Z 14.5K followers, [---] engagements
"Redeye notes that InfraComs Q2 [----] report was below expectations for sales (-9%) and EBITDA (-12%). $INFRA https://www.redeye.se/research/1124090/infracom-q2-2025-a-soft-quarter-awaiting-a-sek178m-windfall https://www.redeye.se/research/1124090/infracom-q2-2025-a-soft-quarter-awaiting-a-sek178m-windfall"
X Link 2025-08-22T07:04Z 14.5K followers, [----] engagements
"Redeye notes that Avtech delivered another solid quarter with net sales growing 37% y/y in line with both preliminary figures and Redeye's estimates. $AVT https://www.redeye.se/research/1124091/avtech-q2-2025-clear-skies-ahead https://www.redeye.se/research/1124091/avtech-q2-2025-clear-skies-ahead"
X Link 2025-08-22T07:05Z 14.5K followers, [----] engagements
"Redeye provides a research update following the Q2 report recently published by Initiator Pharma. $INIT https://www.redeye.se/research/1124157/initiator-pharma-q2-financed-to-explore-vulvodynia https://www.redeye.se/research/1124157/initiator-pharma-q2-financed-to-explore-vulvodynia"
X Link 2025-08-22T10:51Z 14.5K followers, [----] engagements
"Redeye provides an update following CLSs Q2 [----] report. We view the report as strong providing confidence in our forecasts and the companys objectives. $CLS https://www.redeye.se/research/1124336/cls-q2-strong-report-that-reinforces-confidence-in-outlook https://www.redeye.se/research/1124336/cls-q2-strong-report-that-reinforces-confidence-in-outlook"
X Link 2025-08-25T07:05Z 14.5K followers, [---] engagements
"Redeye views InfraComs Q2 [----] results as mixed with a declining top line contrasted by rising EBIT and EBITDA. $INFRA https://www.redeye.se/research/1124537/infracom-a-crucible-of-confidence https://www.redeye.se/research/1124537/infracom-a-crucible-of-confidence"
X Link 2025-08-25T07:05Z 14.5K followers, [---] engagements
"Redeye argues that AVTECH has delivered another strong report with sales growth of 37% y/y which was in line with the Redeye's estimates. $AVT https://www.redeye.se/research/1124443/avtech-no-room-for-turbulence https://www.redeye.se/research/1124443/avtech-no-room-for-turbulence"
X Link 2025-08-25T07:06Z 14.5K followers, [----] engagements
"Redeye har interviewed Claus Elsborg Olesen CEO of Initiator Pharma about the recent Q2 report a strengthened cash position and the strategic expansion into vulvodynia. $INIT https://www.redeye.se/research/1124442/initiator-pharma-q225-interview-with-ceo-claus-elsborg-olesen https://www.redeye.se/research/1124442/initiator-pharma-q225-interview-with-ceo-claus-elsborg-olesen"
X Link 2025-08-25T07:11Z 14.5K followers, [----] engagements
"Redeye gives an initial comment on the positive news that BioArctic has signed an option collaboration and license agreement with Novartis related to its BrainTransporter platform. $BIOA https://www.redeye.se/research/1125081/bioarctic-signs-braintransporter-agreement-with-novartis https://www.redeye.se/research/1125081/bioarctic-signs-braintransporter-agreement-with-novartis"
X Link 2025-08-26T12:19Z 14.5K followers, [----] engagements
"Redeye has interviewed AVTECH's Chief Executive David Rytter to discuss the company's sales pipeline new product developments and strategic management hires. $AVT https://www.redeye.se/research/1125114/avtech-q225-interview-with-ceo-david-rytter https://www.redeye.se/research/1125114/avtech-q225-interview-with-ceo-david-rytter"
X Link 2025-08-27T06:37Z 14.5K followers, [----] engagements
"Redeye makes a correction to our estimates slightly impacting our fair value range for CLS. $CLS https://www.redeye.se/research/1125580/cls-correction-to-our-estimates https://www.redeye.se/research/1125580/cls-correction-to-our-estimates"
X Link 2025-08-28T06:35Z 14.5K followers, [----] engagements
"Redeye initiates coverage of BICO a leading player in the bioconvergence space. $BICO https://www.redeye.se/research/1125575/bico-group-a-forgotten-darling-with-turnaround-potential https://www.redeye.se/research/1125575/bico-group-a-forgotten-darling-with-turnaround-potential"
X Link 2025-08-28T06:40Z 14.5K followers, [----] engagements
"Redeye comments on Dala Energis Q2 report which was again characterised by the strategic restructuring and voluntary share redemption that took place during the quarter. $DE https://www.redeye.se/research/1126009/dala-energi-q2-2025-progressing-steadily https://www.redeye.se/research/1126009/dala-energi-q2-2025-progressing-steadily"
X Link 2025-08-29T08:25Z 14.5K followers, [---] engagements
"Redeye is not surprised by Insplorion's announced directed share issue of SEK6m. $INSP https://www.redeye.se/research/1126060/insplorion-q2-2025-initial-comment https://www.redeye.se/research/1126060/insplorion-q2-2025-initial-comment"
X Link 2025-08-29T10:44Z 14.5K followers, [----] engagements
"Redeye is only making minor changes to our forecasts following Insplorion's Q2 report and other recent events. $INSP https://www.redeye.se/research/1126172/insplorion-large-follow-up-order-in-the-pipeline https://www.redeye.se/research/1126172/insplorion-large-follow-up-order-in-the-pipeline"
X Link 2025-09-01T06:57Z 14.5K followers, [----] engagements
"Redeye updates its estimates and fair value range following Dala Energis Q2 report that was released last Friday. $DE https://www.redeye.se/research/1126285/dala-energi-all-eyes-on-the-nav https://www.redeye.se/research/1126285/dala-energi-all-eyes-on-the-nav"
X Link 2025-09-02T07:46Z 14.5K followers, [----] engagements
"RaySearch Laboratories is trading below Redeyes Base Case. We spoke our analyst about the companys plans to defend market share its vulnerability to further order delays and more. This is a premium article included in our paid plans from SEK 99/month. $RAY https://www.redeye.se/research/1126114/raysearch-laboratories-optimising-cancer-care-through-software https://www.redeye.se/research/1126114/raysearch-laboratories-optimising-cancer-care-through-software"
X Link 2025-09-02T08:10Z 14.5K followers, [----] engagements
"Redeye comments on Ascelia submitting Orviglance to the FDA. The next step is to start the initial filing review process with an FDA confirmation within [--] days from submission. $ACE https://www.redeye.se/research/1126475/ascelia-pharma-a-timely-fda-submission-with-an-extended-cash-runway https://www.redeye.se/research/1126475/ascelia-pharma-a-timely-fda-submission-with-an-extended-cash-runway"
X Link 2025-09-03T10:02Z 14.5K followers, [----] engagements
"Redeye comments on Initiator Pharmas announcement that it has submitted a CTA to the UK authorities for a phase IIa proof-of-concept study of pudafensine in vulvodynia. $INIT https://www.redeye.se/research/1126541/initiator-pharma-cta-submitted-for-phase-iia-study-in-vulvodynia https://www.redeye.se/research/1126541/initiator-pharma-cta-submitted-for-phase-iia-study-in-vulvodynia"
X Link 2025-09-03T14:06Z 14.5K followers, [----] engagements
"Redeye is positive about the FDA clearance to expand the labeling of the Prism system. $CLS https://www.redeye.se/research/1126769/cls-fda-clearance-for-1-5t-mri-guidance https://www.redeye.se/research/1126769/cls-fda-clearance-for-1-5t-mri-guidance"
X Link 2025-09-05T05:56Z 14.5K followers, [----] engagements
"🏆 And the winner is As part of our Q225 Microcap Report we hosted a summer case pitching competition. The winning pitch is now featured in the report - but you can also read all submitted cases on our new #MicrocapCollective https://mcc.redeye.se https://mcc.redeye.se"
X Link 2025-09-09T05:57Z 14.5K followers, [----] engagements
"Redeye return with a research update following BioArctic's Q2 and latest newsflow. $BIOA https://www.redeye.se/research/1126101/bioarctic-strong-momentum-fair-price https://www.redeye.se/research/1126101/bioarctic-strong-momentum-fair-price"
X Link 2025-09-09T06:23Z 14.5K followers, [----] engagements
"Redeye has updated the NGR figures for May based on data from the tax authority where the overall NGR was up 5% Y/Y and up 2% M/M. This is a premium article included in our paid plans from SEK 99/month. https://www.redeye.se/research/1128542/net-gaming-revenues-in-the-swedish-online-gambling-sector-may-7https://www.redeye.se/research/1128542/net-gaming-revenues-in-the-swedish-online-gambling-sector-may-7"
X Link 2025-09-23T07:35Z 14.5K followers, [---] engagements
"Redeye comments on Ascelia raising around SEK30m in a directed share issue - we see this as a sign of strength and give our initial take. $ACE https://www.redeye.se/research/1128559/ascelia-pharma-sek30m-raised-in-a-directed-share-issue https://www.redeye.se/research/1128559/ascelia-pharma-sek30m-raised-in-a-directed-share-issue"
X Link 2025-09-23T07:36Z 14.5K followers, [----] engagements
"Redeye comments on todays news from Cheffelo where financial targets have been raised ahead of its now scheduled CMD. $CHEF https://www.redeye.se/research/1128667/cheffelo-raising-the-steaks https://www.redeye.se/research/1128667/cheffelo-raising-the-steaks"
X Link 2025-09-24T07:12Z 14.5K followers, [----] engagements
"Redeye has interviewed Magnus Corfitzen CEO of Ascelia Pharma regarding recent positive newsflow; including the NDA submission to FDA for Orviglance and a directed share issue of SEK 30m. $ACE https://www.redeye.se/research/1128911/ascelia-pharma-interview-with-ceo-magnus-corfitzen-4 https://www.redeye.se/research/1128911/ascelia-pharma-interview-with-ceo-magnus-corfitzen-4"
X Link 2025-09-26T09:16Z 14.5K followers, [----] engagements
"Redeye leaves a short comment on CLSs fully subscribed warrants program (TO8B). $CLS https://www.redeye.se/research/1129114/cls-fully-subscribed-to8b-program-as-expected https://www.redeye.se/research/1129114/cls-fully-subscribed-to8b-program-as-expected"
X Link 2025-10-01T06:34Z 14.5K followers, [---] engagements
"Redeye Investor Forum Online last out [-----] Elicera Therapeutics Jamal El Mosleh CEO [-----] Ferroamp William Ryan CFO [-----] Climeon Lena Sundquist CEO Tune in: https://www.redeye.se/events/1109578/investor-forum-online-38tab=schedule https://www.redeye.se/events/1109578/investor-forum-online-38tab=schedule"
X Link 2025-10-02T13:07Z 14.5K followers, [---] engagements
"Redeye is positive about the results from CLSs study at Skne University Hospital. $CLS https://www.redeye.se/research/1129930/cls-solid-results-from-sus-study https://www.redeye.se/research/1129930/cls-solid-results-from-sus-study"
X Link 2025-10-08T09:55Z 14.5K followers, [---] engagements
"Physitrack is trading below Redeye's Base Case. We spoke with our analyst regarding the the current expectations for the following report Physitrack's strategy to convert the Nexa/Physitrack partnership into broader Wellness traction and other key topics. This is a premium article included in our paid plans from SEK 99/month. $PTRK https://www.redeye.se/research/1130285/physitrack https://www.redeye.se/research/1130285/physitrack"
X Link 2025-10-14T08:19Z 14.5K followers, [---] engagements
"#tech #growth Imponerande bolag under kraftig tillvxt se video p $HTRO $POLYG $LEO $NEON http://beta.redeye.se/member/dashboard/all-companies/502310/techbolag-med-imponerande-tillvaxt/members_content http://beta.redeye.se/member/dashboard/all-companies/502310/techbolag-med-imponerande-tillvaxt/members_content"
X Link 2016-09-14T16:12Z 14.5K followers, [--] engagements
"No drama in @Heliospectra balance sheet for liquidation purposes is a formality notes Joel Westerstrm @Qwertyrius http://beta.redeye.se/company/heliospectra/506381/no-drama-heliospectra-s-announcement-it-will-prepare-balance-sheet-liquidation-purposes#company-navigation http://beta.redeye.se/company/heliospectra/506381/no-drama-heliospectra-s-announcement-it-will-prepare-balance-sheet-liquidation-purposes#company-navigation"
X Link 2016-10-14T12:54Z 14.7K followers, [--] engagements
"$NUE We have now initiated analyst coverage of #Nuevolution - Read the first analysis by Mathias Spinnars at: http://beta.redeye.se/company/nuevolution/531509/nuevolution-nue-hope-drug-discovery#company-navigation http://beta.redeye.se/company/nuevolution/531509/nuevolution-nue-hope-drug-discovery#company-navigation"
X Link 2017-03-30T06:25Z 14.7K followers, [--] engagements
"$FPIP Steady growth in recurring revenues in @Formpipe during Q1 Johan Svantesson comments: http://beta.redeye.se/company/formpipe-software/535018/formpipe-q1-comment-steady-growth-recurring-revenues#company-navigation http://beta.redeye.se/company/formpipe-software/535018/formpipe-q1-comment-steady-growth-recurring-revenues#company-navigation"
X Link 2017-04-24T10:01Z 14.5K followers, [--] engagements
"$IMINT We are expecting an exciting [----] for #IMINT - download our new analysis at: http://beta.redeye.se/company/imint-image-intelligence/535049/imint-expecting-exciting-2017 http://beta.redeye.se/company/imint-image-intelligence/535049/imint-expecting-exciting-2017"
X Link 2017-04-24T12:23Z 14.5K followers, [--] engagements
"Increased profitability in @Formpipe $FPIP leads to Johan Svantesson raising our fair value range in his update: http://beta.redeye.se/company/formpipe-software/539120/formpipe-continues-increase-profitability#company-navigation http://beta.redeye.se/company/formpipe-software/539120/formpipe-continues-increase-profitability#company-navigation"
X Link 2017-04-28T07:06Z 14.5K followers, [--] engagements
"$ANOD Our analyst Kristoffer Lindstrm @Lindstroem_K has published an updated analysis of #AddnodeGroup. Read it at: http://beta.redeye.se/company/addnode-group/540323/addnode-group-new-market-region#company-navigation http://beta.redeye.se/company/addnode-group/540323/addnode-group-new-market-region#company-navigation"
X Link 2017-05-04T10:18Z 14.5K followers, [--] engagements
"New agreement with large Chinese manufacturer signed by $IMINT @vidhance confirming Dennis Berggren's view on case: http://beta.redeye.se/company/imint-image-intelligence/545266/imint-signs-development-agreement-chinese-smartphone-producer http://beta.redeye.se/company/imint-image-intelligence/545266/imint-signs-development-agreement-chinese-smartphone-producer"
X Link 2017-06-02T14:03Z 14.5K followers, [--] engagements
"#Formpipe will release their Q2 report on Friday. Take part of our expectations here: $FPIP https://www.redeye.se/company/formpipe-software/550376/formpipe-q2-preview#company-navigation https://www.redeye.se/company/formpipe-software/550376/formpipe-q2-preview#company-navigation"
X Link 2017-07-12T08:35Z 14.5K followers, [--] engagements
"Q2 comment @Formpipe: More SaaS affects earnings in the short term. Read our comment here: $FPIP https://www.redeye.se/company/formpipe-software/550775/formpipe-q2-comment-more-saas-affects-earnings-short-term#company-navigation https://www.redeye.se/company/formpipe-software/550775/formpipe-q2-comment-more-saas-affects-earnings-short-term#company-navigation"
X Link 2017-07-14T09:06Z 14.5K followers, [--] engagements
"$FPIP Increase in SaaS deliveries affected Q2 negatively in @Formpipe - positive with +8% recurring revenues Y/Y: https://www.redeye.se/company/formpipe-software/551428/formpipe-increase-saas-deliveries-affected-q2-negatively https://www.redeye.se/company/formpipe-software/551428/formpipe-increase-saas-deliveries-affected-q2-negatively"
X Link 2017-07-20T06:12Z 14.5K followers, [--] engagements
"Expectations of Q2 - #Imint. We expect net revenues to come in about SEK 3.6m and EBIT around SEK -2.1m. $IMINT https://www.redeye.se/company/imint-image-intelligence/554729/imint-expectations-q2#company-navigation https://www.redeye.se/company/imint-image-intelligence/554729/imint-expectations-q2#company-navigation"
X Link 2017-08-21T07:14Z 14.5K followers, [--] engagements
"Q2 Sales higher than expected - #Imint. Dennis Berggren gives his first comment. @vidhance $IMINT https://www.redeye.se/company/imint-image-intelligence/554907/imint-q2-sales-higher-expected#company-navigation https://www.redeye.se/company/imint-image-intelligence/554907/imint-q2-sales-higher-expected#company-navigation"
X Link 2017-08-22T11:30Z 14.5K followers, [--] engagements
"$FPIP: EBIT and the EBIT-margin were better than our expectations - @Formpipe. Read our report comment: https://www.redeye.se/company/formpipe-software/566852/formpipe-stable-growth-recurring-revenuesutm_medium=RSS&utm_source=redeye https://www.redeye.se/company/formpipe-software/566852/formpipe-stable-growth-recurring-revenuesutm_medium=RSS&utm_source=redeye"
X Link 2017-10-26T14:57Z 14.5K followers, [--] engagements
"First comment - $IMINT. "We had expected a somewhat stronger quarter." writes our analyst Dennis Berggren https://www.redeye.se/company/imint-image-intelligence/579334/imint-no-major-surprises https://www.redeye.se/company/imint-image-intelligence/579334/imint-no-major-surprises"
X Link 2018-02-23T10:08Z 14.5K followers, [--] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing